Mental Disorder

A mental disorder is a clinically significant disturbance in a person's cognition, emotional regulation, or behavior, usually understood as a pattern of symptoms that causes distress or impairment and reflects dysfunction in psychological, biological, or developmental processes. Major classification systems, the International Classification of Diseases (ICD-11) and the American Psychiatric Association's DSM-5-TR, define disorders through observable syndromes rather than established causes. The terms "mental illness," "psychiatric disorder," and "mental health condition" are often used interchangeably, although the choice of label is itself debated among clinicians, researchers, and people with lived experience. Related fields include psychology, psychoanalysis, and neuroscience, and the broader topic sits within mental-health and public-health.

Mental disorders are among the most significant causes of health loss worldwide. The World Health Organization reports that in 2023 nearly one in seven people, about 1.2 billion, were living with a mental disorder, with anxiety and depressive disorders the most common. Disorders such as schizophrenia and bipolar disorder are associated with substantial premature mortality, and treatment gaps are wide, particularly in low-income countries. These facts make the topic central to WHO policy, health system design, and debates about human-rights and disability.

This entry first examines how the concept of mental disorder has been defined and classified, from ancient humoral theories through the modern manuals, and then surveys the major diagnostic categories and their global prevalence. It turns to causes, diagnosis, psychological and biological treatments, and the organization of care, before addressing prevention, stigma and legal rights, cultural variation, and unresolved controversies. It closes with current research directions in dimensional models, biomarkers, and precision psychiatry.

Defining Mental Disorder

The overarching definition used by the American Psychiatric Association, carried from the DSM-5 into the DSM-5-TR, treats a mental disorder as a syndrome. It is a cluster of disturbances in cognition, emotion regulation, or behavior that points back to a breakdown in the psychological, biological, or developmental processes behind mental functioning A mental disorder is a syndrome characterized by clinically significant disturbance in an individual's cognition, emotion regulation, or behavior that reflects a dysfunction in the psychological, biological, or development processes underlying mental functioning. The definition contains three working elements. The first is distress or impairment in social, occupational, or other important activity, which the wording presents as typical rather than strictly obligatory Mental disorders are usually associated with significant distress or disability in social, occupational, or other important activities. The DSM-5 wording indicates that mental disorders are usually associated with significant distress or impairment. The second is the requirement of an underlying dysfunction, which separates a disorder from a merely unpleasant state. The third is a normative exclusion: a reaction that is expectable, or culturally approved, toward a common stressor or loss does not qualify An expectable or culturally approved response to a common stressor or loss, such as the death of a loved one, is not a mental disorder.

Where the Boundaries Blur

Each element is difficult to apply in practice. Bereavement is the standard example of an excluded response, yet the DSM-5-TR added prolonged grief disorder for grief that persists and disrupts functioning, showing how the line between extreme but adaptive reaction and disorder is redrawn by committee judgment rather than discovered in nature New diagnostic entities, such as prolonged grief disorder, have been added to reflect evolving understandings in the field.. The social-deviance clause is intended to stop the diagnosis from policing unconventional political, religious, or sexual conduct. Its exception, however, requires that the deviance result from an individual dysfunction, and deciding that requires a prior view of what normal functioning is Socially deviant behaviour (e.g., political, religious, or sexual) and conflicts that are primarily between the individual and society are not mental disorders unless the deviance or conflict results from a dysfunction in the individual. Since what counts as impairment also varies across social settings, the thresholds that separate disorder from variation rest on consensus rather than a natural boundary.

Harmful Dysfunction and Value-Laden Accounts

Jerome Wakefield's harmful dysfunction analysis attempts to combine a scientific and a value component. Under this view, a disorder requires two individually necessary but only jointly sufficient conditions: dysfunction, a mechanism failing to perform the function it was designed for by natural selection, and harm, a value judgment that this dysfunction is undesirable. Critics contend that the dysfunction half is not purely factual, because it is intrinsically normative, and that for most psychiatric conditions the mechanism involved is unknown, which makes the evolutionary standard hard to apply the term dysfunction is not purely factual but intrinsically normative/evaluative. Other theorists argue that the value judgment is the decisive element, entering when a behavior is declared harmful For Wakefield, the value judgment enters at the point of declaring that some behavior is harmful.. An alternative proposal by Lilienfeld and Marino treats disorder as a prototype-like concept without a clear-cut boundary we propose an alternative analysis of disorder, including mental disorder, as a Roschian concept lacking a clear-cut coun. No single biological marker, such as a blood test, brain scan, or genetic variant, is accepted as defining most disorders, so classification continues to depend on clinical syndromes and their consequences.

Neurology and the Boundary Cases

Dementia shows how the boundary with neurology is drawn differently across systems. ICD-10 classed dementia under a broad definition of mental disorder, while Alzheimer disease itself was coded in the neurological chapter From a classificatory hierarchical standpoint ICD-10 dementia was classed under a simple definition of "mental disorder" that did not In the neurological chapter, Alzheimer disease is listed under G30.. In ICD-11, dementia falls under a narrower definition of mental disorder and within a neurocognitive disorders grouping In ICD-11 dementia appears under a more specific definition for "mental disorder" and under the restricted diagnostic grouping "neurocognitive disorders".. Dementia itself is not coded in either system; a specific etiology must be added before it becomes codable In both classifications, dementia is not coded. Adding a specific etiology from the chapter itself, or from a different chapter in the classification, changes its nosology status to a disorder which allows coding.. Interpretations differ. One commentary reads the ICD-11 relocation as recognizing dementia as primarily neurological This relocation recognizes dementia as primarily a neurological condition, rather than a mental disorder., whereas the 2019 international consensus kept dementia categories in chapter 6 and placed underlying causes in chapter 8 the dementia categories being included in chapter 6 and their underlying causes being represented in chapter 8, following the logic of ICD-10..

Terminology: Disorder, Illness, and Condition

The three terms carry different connotations, and clinicians and researchers choose among them for different purposes. "Disorder" is the formal term in the DSM and ICD, and it signals a classification-level judgment that functioning has departed from a standard; it can, however, sound like disorderliness or personal failure. "Illness" centers the lived experience of being unwell and the social role of the sick person, which can reduce blame but may also extend medical authority over problems of living. "Condition" is the most neutral term and is common in disability and neurodiversity discourse. That movement holds that the supporters of the neurodiversity movement contend that autism is not a mental disorder, but rather a natural human variation. Each label shapes how patients see themselves and how employers, insurers, and the public respond, so the choice of term is itself a clinical and ethical decision.

Historical Conceptions

For most of recorded history, severe mental suffering was explained through the body, the soul, or the supernatural, and the category of "mental disorder" as a single medical entity did not yet exist. The most durable ancient framework was humoral theory, which held that health depended on the balance of blood, phlegm, yellow bile and black bile. Hippocratic physicians linked the melancholic temperament and depressive states to an excess of black bile, and the word melancholia still preserves that origin. Plato noted the many forms of distress that black bile could produce, and later writers in the Greco-Roman and Islamic traditions, including Galen, Celsus and Avicenna, extended the theory. Treatments followed from it: bloodletting, purging and other measures were meant to restore the humoral balance, and such ideas remained influential in European medicine into the nineteenth century.

Medieval and early modern Europe often read madness through spiritual and moral categories. Unusual or disruptive behaviour could be interpreted as demonic possession, divine punishment or sin, and from the late fifteenth century witch-hunting literature gave such interpretations a systematic, and dangerous, form. Care for the insane was uneven and largely the responsibility of families, parishes and charitable institutions. Many people deemed mad were confined in prisons, almshouses and workhouses alongside the poor and the criminal. The London hospital of St Mary of Bethlehem, which began admitting the mentally ill in the early fifteenth century, gave its name to "bedlam" as a word for chaos. In seventeenth-century France, the state-supported general hospitals grouped beggars, the sick and the insane together. Later historians, most prominently Michel Foucault, interpreted this period of confinement as a form of social exclusion rather than therapy, although that reading has been debated.

The asylum movement of the late eighteenth and nineteenth centuries changed these arrangements. In Paris, Philippe Pinel took charge of the Bicêtre hospital in the early 1790s and removed the chains from patients, reframing them as ill people who could be treated rather than dangerous criminals. In England, the Quaker William Tuke founded the York Retreat, where small numbers of residents worked, read and took part in a structured, family-like routine in a rural setting. These approaches, known as moral treatment, rested on the belief that madness was curable and that a well-ordered environment could restore reason. Pinel's Treatise on Insanity (1801) helped spread these ideas. Asylums also became custodial institutions as their populations grew: in France the number of patients rose from about 10,000 in 1840 to more than 60,000 by 1900, and optimism about moral treatment faded as industrialization and immigration filled hospitals.

Within these asylums, physicians began to organize their observations into recognizable clinical patterns. Pinel had already separated conditions such as melancholia, mania and dementia, and his successors refined these syndromes by course, symptom profile and outcome. This shift from general notions of madness to specific entities, observed in patients over time, is a precursor of the modern idea of a disorder defined by a cluster of symptoms.

The most influential nineteenth-century restructuring came from the German psychiatrist Emil Kraepelin. Drawing on large numbers of asylum cases, Kraepelin separated the chronic, early-onset, progressive illness he called dementia praecox from manic-depressive insanity, which he regarded as episodic, with periods of remission between episodes. Kraepelin's rule that course and outcome should define the two groups was later revised; by 1912 he acknowledged that recovery could occur in dementia praecox and placed greater weight on bizarre delusions and passive symptoms. The Swiss psychiatrist Eugen Bleuler criticized the name, because the illness did not always begin in adolescence or end in decline, and in his 1911 monograph he proposed "schizophrenia," emphasizing the splitting of psychic functions as a central feature. Bleuler kept Kraepelin's subtypes and added others, including simple and latent forms. The resulting Kraepelinian dichotomy, with schizophrenia on one side and what is now bipolar disorder on the other, shaped twentieth-century classification, although the boundary between the two has repeatedly been questioned.

In the twentieth century, psychoanalysis offered a rival account of mental disorder. Sigmund Freud, trained in neurology, developed a psychodynamic theory of unconscious conflict that was largely separate from Kraepelin's nosology. Psychoanalytic thinking treated neuroses, such as hysteria, obsessional states and anxiety, as expressions of inner conflict and early experience rather than as fixed brain diseases, and it gave the term "neurosis" a central place in clinical language. Psychodynamic ideas strongly shaped the first edition of the American Psychiatric Association's diagnostic manual, published in 1952, which described many conditions as reactions to life circumstances. From the 1960s onward, criticism of psychoanalytic concepts for weak reliability and limited empirical support, together with the growth of biological and research-oriented psychiatry, reduced its role. The 1980 DSM-III abandoned the neurosis category and adopted explicit, descriptive criteria, marking the decisive move away from psychoanalysis as the organizing framework of diagnosis, although psychodynamic therapies continued to be practised and studied.

Modern Classification Systems

The American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM) began in 1952 as a short handbook. The first edition was a slim pamphlet of about 32 pages covering 106 diagnoses, and it drew on the military's wartime Medical 203 system and on the sixth edition of the WHO's International Classification of Diseases (ICD-6). Its categories were read through psychodynamic theory, and all disorders were considered reactions to events in a person's environment. The 1968 DSM-II kept this framework, and both early editions were used mostly for administration rather than for detailed clinical work.

DSM-III, published in 1980, changed the approach. It was built around explicit, symptom-based criteria, and it dropped the preferred etiology of earlier editions, which is why it is described as atheoretical. Its criteria drew on research-diagnostic work from the 1970s, including the Feighner criteria and the Research Diagnostic Criteria led by Robert Spitzer. The number of diagnoses rose from 182 to 265, and the manual also introduced a multiaxial format. Critics have argued that the approach was not as neutral as it claimed. Its symptom-based focus fit a biological model well, and its reliability gains made large drug trials easier to run. Later revisions have been regular: DSM-IV (1994), DSM-5 (2013), and the text revision DSM-5-TR (2022). The DSM-5 dropped the multiaxial system, and the 2013 edition runs to roughly 300 conditions. Each revision has been contested by task forces, and the editions have grown in length.

The ICD has its own history. ICD-6 was the first ICD edition to include a section on mental disorders, and the DSM and ICD have been linked since the 1960s. DSM-II was designed to align with ICD-8, and later DSM editions have tried to remain compatible with each new ICD version. ICD-11 was released by the WHO in 2018 and approved by the World Health Assembly in 2019, and it took effect in 2022. Its mental-health chapter, Chapter 06 "Mental, Behavioural or Neurodevelopmental Disorders" (MBND), defines these conditions as syndromes marked by clinically significant disturbance in cognition, emotional regulation, or behaviour, reflecting a dysfunction in psychological, biological, or developmental processes. The chapter is organised into groupings that run from neurodevelopmental disorders and schizophrenia through to neurocognitive disorders, with sleep-wake disorders and sexual health conditions placed in separate chapters.

From categories to dimensions

Both systems have moved, at least in part, away from purely categorical diagnosis toward dimensional description, most clearly for personality disorders. DSM-5 included an optional Alternative Model for Personality Disorders (AMPD) in Section III, which combined an assessment of impairment in self and interpersonal functioning with trait domains. Its impairment scale runs from no impairment to extreme impairment. Its five trait domains are negative affectivity, detachment, antagonism, disinhibition, and psychoticism. The ICD-11 model is purely dimensional. It rates personality dysfunction as personality difficulty, or as mild, moderate, or severe personality disorder. It then adds up to five trait domain qualifiers, namely negative affectivity, detachment, dissociality, disinhibition, and anankastia, along with a borderline pattern qualifier. ICD-11 has dropped every traditional personality disorder category except borderline. The two models overlap in four trait domains, but the fifth differs, with anankastia (compulsivity) in ICD-11 and psychoticism in DSM-5.

Differences in thresholds and organisation

The two systems also differ in where they draw the line for diagnosis, in their wording, and in how they group conditions. Childhood chronic irritability is a clear example. DSM-5 added disruptive mood dysregulation disorder (DMDD) in 2013 to describe severe, persistent irritability in young people, partly to reduce the diagnosis of bipolar disorder in children. ICD-11 has no equivalent category, so the same presentation is handled differently depending on the system used. Bipolar disorder is a similar case. The two classifications differ in their episode requirements, in how they describe mixed presentations, and in the specifiers they permit, so the same person may receive different labels under each system. These differences matter for epidemiological comparisons, for research samples, and for the translation of guidelines between countries.

Why classification is descriptive

Modern classifications describe clusters of symptoms and signs rather than the causes behind them. The main reason is that no established pathophysiology or validated biomarker currently identifies most disorders. Without these markers, a diagnosis rests on observable features and on patterns of distress or impairment. This approach improves agreement between clinicians and allows research and treatment trials to be compared across sites. Its limits are also widely acknowledged. Diagnostic labels can seem to explain what they only describe, and their stability over time depends on the consensus of task forces rather than on biological findings. For this reason, many researchers now treat categories as provisional and look to dimensional and transdiagnostic models as a way to capture overlapping symptoms more accurately.

Major Diagnostic Categories

Classification systems group mental disorders into families that share age of onset, clinical features, and course. The groupings below follow broad DSM-5-TR and ICD-11 practice. The two systems differ in detail, and those differences are covered in the classification section.

Neurodevelopmental disorders

Neurodevelopmental disorders, including autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and intellectual disability, usually emerge in childhood, often before school age. Prevalence figures depend heavily on the method used. In the United States, the CDC's surveillance network estimates that about 1 in 31 (3.2%) children aged 8 years has been identified with ASD. Parent-reported surveys produce higher figures for ADHD. A 2022 national survey found that an estimated 7 million (11.4%) U.S. children aged 3–17 years have ever been diagnosed with ADHD, and boys were diagnosed considerably more often than girls. Autism is also reported in boys at a much higher rate than in girls. These conditions frequently co-occur: one estimate found that approximately 13% of children who were diagnosed with ADHD were also diagnosed with ASD. Intellectual disability is defined by limits in intellectual functioning together with limits in adaptive behavior.

Schizophrenia spectrum and other psychotic disorders

Psychosis is the central feature of this group. The hallmark symptom of schizophrenia is psychosis, such as experiencing auditory hallucinations (voices) and delusions (fixed false beliefs). Disorganized speech and behavior, negative symptoms such as reduced emotional expression and diminished motivation, and cognitive deficits are also part of the clinical picture. The disorder typically usually begins in adolescence or early adulthood. Before overt psychosis, a prodromal phase may involve withdrawal or isolation, irritability, suspiciousness, unusual thoughts, perceptual distortions, and disorganization. Onset of full psychotic symptoms can be abrupt or gradual. Diagnosis requires that symptoms persist; one or more episodes of symptoms must last ≥ 6 months before the diagnosis is made. Shorter presentations fall under related categories such as schizophreniform disorder and brief psychotic disorder. Some researchers regard schizophrenia as a heterogeneous group rather than a single illness. One reference work describes it as a brain disorder that probably comprises several separate illnesses.

Depressive and bipolar disorders

Major depressive disorder involves a persistent low mood or loss of interest in activities, and it is distinct from ordinary emotional fluctuation. WHO estimates that globally, an estimated 5.2% of adults suffer from depression. Women are affected more often than men. Dysthymia, which DSM-5 renamed persistent depressive disorder, is a chronic, lower-grade depression lasting at least two years in adults. Bipolar disorders are defined by episodes of elevated mood. Bipolar I requires at least one manic episode, lasting roughly a week or leading to hospitalization. Bipolar II requires at least one hypomanic episode, which is shorter and less severe, together with a major depressive episode, and it never includes a full manic episode. The distinction matters clinically because the two forms are treated differently and carry different risks of relapse and functional impairment.

Anxiety, obsessive-compulsive, and trauma- and stressor-related disorders

Anxiety disorders, which include generalized anxiety disorder, panic disorder, social anxiety disorder, and specific phobias, are the most common group. WHO reports that anxiety disorders are the world's most common mental disorders, affecting 470 million people in 2023. Their defining feature is excessive fear and worry and related behavioural disturbances. Symptoms often appear in childhood or adolescence, and girls and women are more likely to experience an anxiety disorder than boys and men. DSM-5 places obsessive-compulsive disorder in its own chapter, separate from anxiety disorders, because of its distinct features and treatment. Trauma- and stressor-related disorders, such as post-traumatic stress disorder, require exposure to a traumatic or stressful event as a diagnostic precondition, and they are characterized by intrusive re-experiencing, avoidance, and changes in arousal and mood.

Eating, substance-related, personality, and neurocognitive disorders

Eating disorders, including anorexia nervosa, bulimia nervosa, and binge-eating disorder, are defined by disturbed eating patterns and an excessive concern with body weight or shape. DSM-5 also includes avoidant/restrictive food intake disorder. Substance-related and addictive disorders are diagnosed on a severity scale rather than as separate abuse and dependence categories. DSM-5 combines them into a single substance use disorder graded by the number of criteria met, and it includes gambling disorder among non-substance conditions. ICD-11 groups addictive behaviours differently.

Personality disorders are enduring patterns of inner experience and behaviour that depart markedly from cultural expectations. In DSM-5's categorical scheme, they are grouped into clusters A, B, and C, and DSM-5 Section III also offers a dimensional model. Borderline features are a common target of specialized psychotherapy. Neurocognitive disorders are acquired declines in cognitive function from a previous level of performance, and they range from mild to major. Dementia is the best-known example. Where these conditions belong, whether in mental disorder chapters or neurological chapters, varies between systems and is addressed in the boundary discussion.

Across all of these groups, diagnosis relies on symptom patterns, duration, and functional impairment, usually gathered through interview and collateral history. Substantial comorbidity between categories is common, and diagnostic boundaries are often drawn by convention rather than by established biology.

Epidemiology and Global Burden

Prevalence figures for mental disorders depend heavily on the study, the year and the method. WHO's fact sheets draw on the 2021 round of the Global Burden of Disease (GBD) study, while the newest estimates come from the GBD 2023 collaboration. Most figures below are therefore modelled rather than counted. Country and regional numbers are modelled statistical estimates with a margin of uncertainty, not tallies of diagnosed cases.

In 2021, 14% of the global population, more than one billion individuals, were estimated to be living with a mental disorder. Anxiety and depressive disorders dominated this total. WHO reports put anxiety at about 4.4% and depressive disorders at about 4% of the population, while schizophrenia (0.3%) and bipolar disorder (0.5%) were far less common. In 2021, global prevalence reached 359.2 million cases of anxiety disorders and 332.4 million cases of depressive disorders. The 2023 WHO estimates were higher for anxiety: 470 million people had an anxiety disorder, making anxiety disorders the most common of all mental disorders. For depression, approximately 322 million people were affected. Because the 2021 and 2023 figures come from different GBD rounds and different modelling, they should not be read as a simple year-on-year rise. Still, prevalence has grown over time: the number of people with mental disorders increased between 2011 and 2021, faster than in the preceding decade.

Women are affected more often than men, particularly by depression and anxiety. In 2023, 6.2% of adult women had depression compared with 4.1% of men. Age-standardised anxiety DALY rates for women are around 1.6 times those of men in GBD 2019 data. Age patterns differ by condition. Symptoms of anxiety often begin in childhood or adolescence. In the 10–14 age group, the leading subtypes by DALY rate were anxiety disorders, conduct disorder and depressive disorders. Depression's burden is largest in absolute terms among adults aged 25–45, while the age-specific rate peaks later, at ages 60–64.

The main burden measure is the disability-adjusted life year. DALYs are estimated from years of life lost (YLLs) and years lived with disability (YLDs). Years lived with disability are calculated by multiplying prevalence by a disability weight. On this basis, mental disorders account for one in twenty DALYs globally. The share is larger when only disability is counted: 17% of the total years lived with disability in the world were due to mental disorders in 2023. In GBD 2019, depressive disorders accounted for the largest proportion of mental disorder DALYs (37.3%), followed by anxiety disorders (22.9%) and schizophrenia (12.2%). Trends are mixed. Between 1990 and 2021, the age-standardised DALY rate for anxiety disorders increased by 18.2% and for depressive disorders by 13.4%, with population growth accounting for most of the increase.

Severe disorders carry excess mortality. In 2021, an estimated 727 000 people died by suicide. Suicide is a leading cause of death among young people. Life expectancy is substantially reduced in schizophrenia and bipolar disorder, mainly because of suicide and higher rates of physical illnesses such as cardiovascular and metabolic disease. Those patterns are not quantified in the sources consulted for this section.

Economic costs are large but hard to pin down. One figure often cited from WHO data is US$1 trillion per year in global productivity lost to depression and anxiety. Estimates of this kind are typically based on productivity losses and indirect costs rather than direct treatment spending. National studies show the same scale: depression and anxiety are estimated to cost $247 billion a year in the United States.

Measurement choices also shape these numbers. Incidence counts new cases arising within a defined time period, measuring how fast a disorder is spreading. Past-year prevalence instead records the proportion of a population who met criteria for a disorder at any point in the past 12 months. Survey and clinical-record data can diverge sharply. In a Southern California cohort of young people, clinically diagnosed depression increased by approximately 60% from 2017 to 2021. National survey data show smaller shifts, such as depression among children aged 3 to 17 rising from 3.1% in 2016 to 4.0% in 2020. Part of this gap reflects changes in help-seeking and diagnosis, not just in underlying illness.

Biological Causes and Risk

Biological research has established that most mental disorders run in families and involve many genes of small effect, but it has not identified a single mechanism or marker that defines any major diagnosis. The oldest tools are twin, family, and adoption designs. Twin studies compare how often identical and fraternal twins share a condition. Heritability is a population-level statistic: it describes how much of the variation in a trait across a particular population tracks genetic differences, and it does not measure how much a given person's illness is "genetic." Meta-analyses of twin data put heritability near 0.8 for schizophrenia, around 0.37 for major depression, and roughly 0.5 for alcohol use disorder, so the figures differ substantially between conditions. Adoption studies help separate shared genes from shared household environments, but both designs depend on the range of environments in their samples. They rarely include extreme neglect or abuse, and they say little about rare single-gene mutations.

Genome-wide association studies (GWAS) scan millions of common genetic variants and compare their frequency in people with and without a diagnosis. These studies have found many loci, each with a very small effect. Researchers combine these weak signals into polygenic risk scores, which can rank people by statistical liability, but the scores explain only a modest share of differences between individuals and cannot diagnose anyone. Cross-disorder analyses have revealed extensive overlap. A 2013 analysis by the Psychiatric Genomics Consortium identified loci shared across five disorders, and a later study of eight conditions, involving more than 725,000 cases and controls, sorted them into genetic clusters that do not match the traditional diagnostic categories. Genetic correlations between schizophrenia and bipolar disorder are high, and studies of mood instability point to shared gene sets involved in synapse organization. These findings suggest that diagnostic boundaries do not map neatly onto biological boundaries, and that a common underlying vulnerability may appear as different syndromes.

Neurotransmitter hypotheses have a long history but a mixed evidential record. The monoamine hypothesis of depression proposed that low activity of serotonin, noradrenaline, or dopamine underlies depressive illness. It grew out of observations that drugs raising monoamine levels relieved symptoms. Yet studies of monoamine metabolites in urine, plasma, and cerebrospinal fluid have not found a consistent metabolic abnormality in depressed patients as a group. Some subgroups show reduced serotonin and dopamine metabolites, and depletion experiments can worsen mood in vulnerable people, but these effects are not universal. The delay of several weeks before antidepressants take effect, despite rapid changes in monoamine levels, indicates that the drugs act through downstream adaptations. Most researchers therefore regard the monoamine model as incomplete rather than wrong. The dopamine model of psychosis has a stronger pharmacological basis, since antipsychotics block dopamine D2 receptors and stimulant drugs can produce psychotic symptoms. Imaging studies have reported elevated dopamine synthesis in people with psychosis, particularly around illness onset. However, the model does not account well for negative symptoms or cognitive deficits, and it is now usually integrated with glutamatergic and other systems.

Neuroimaging has documented group-level differences in brain structure and function, using MRI, functional MRI, and PET. Studies have reported reduced volumes in some regions in schizophrenia, altered connectivity networks in mood disorders, and changes in serotonin receptor binding in depression. These differences are typically small, overlap substantially with the normal range, and vary with medication, age, and scanner or analysis method. Many early findings were based on small samples and failed to replicate, and larger multi-site consortia have since produced more modest but more reliable estimates. At present, imaging cannot diagnose an individual, so it is primarily a research tool rather than a clinical biomarker.

Prenatal and perinatal exposures, along with neuroendocrine and immune processes, add further risk. Maternal infection, severe malnutrition, obstetric complications such as hypoxia, preterm birth, and advanced paternal age have each been associated with modestly higher rates of later psychiatric disorders. Chronic stress can dysregulate the hypothalamic-pituitary-adrenal axis, and many depressed patients show elevated cortisol. A subset of patients also shows raised inflammatory markers, which has prompted interest in immune-targeted treatments, though this has not yet translated into a broadly applicable approach. Substance use is a major and partly causal factor. Heavy adolescent cannabis use is associated with earlier onset of psychosis, and alcohol and stimulant use are linked to depression, anxiety, and psychotic symptoms. Because these associations may run in both directions, and because people with genetic or early-life vulnerability are more likely to use substances, these biological factors are best understood as interacting with, rather than replacing, psychological and social determinants.

Notes on sources: twin heritability figures are from a meta-analysis cited in the alcohol use disorder study and the schizophrenia/depression estimates it reports; genomic findings are from cross-trait GWAS papers and a Mass General Advances summary; the monoamine and dopamine evidence draws on reviews and the NCBI Basic Neurochemistry chapter.

Psychological and Social Determinants

The main conceptual framework for these risk factors is the diathesis-stress model. In its basic form, diatheses interact with stress to bring about mental illness, and neither factor is sufficient alone. Psychological diatheses are relatively stable individual differences (e.g., personality traits or cognitive styles). The idea was applied to mental disorders in the 1960s, when Paul Meehl used it for schizophrenia. Later neurobiological versions focused on stress-hormone signalling. In 1997, a "neural diathesis-stress" model of psychosis focused on the role of the hypothalamic-pituitary-adrenal (HPA) axis in triggering and exacerbating psychotic symptoms. The model also has critics. It has also faced criticism for being overly simplistic, as it does not account for the complexity of mental health issues, and it does not consider the role of social support, personal outlook, or cumulative stressors. Its molecular evidence is mixed: one founding demonstration failed to replicate, yet its core interactionist logic keeps finding support at a larger scale. A 2018 study that tested a polygenic score against stressful life events found the predicted gene-by-stress interaction for depression.

Childhood adversity is one of the best-documented sources of vulnerability. A systematic review and meta-analysis found a significant association between the following childhood exposures and adult mental disorder (1.24 ≤ Odds ratios ≤ 2.09): bullying (victimhood, and frequency); emotional abuse; neglect; physical abuse; parental loss; and general maltreatment. The same review found that the result for sexual abuse was not statistically significant, and it suggested this may reflect how that exposure was assessed prospectively. The association also shows a dose-response pattern. Among those with multiple forms of maltreatment, the odds of developing a mental disorder were two and a half times higher. In a psychosis-focused dose-response meta-analysis, the pooled odds ratio increased from 1.76 for 1 exposure to 6.46 for 5+ exposures compared to no traumatic experience. Risk also appears to rise with age at assessment, with the smallest effect observed among children and the largest among adults. However, the evidence on genetic moderation is weaker: across available studies, evidence for an interaction between childhood adversity and 5-HTTLPR genotype was limited.

Cognitive and learning-based accounts describe how these vulnerabilities become symptoms. Negative patterns of interpretation about the self, the world, and the future are thought to maintain depression and anxiety. Avoidance can keep anxiety going by preventing the disconfirmation of feared outcomes. Conditioned fear, in which neutral cues come to predict danger through association, is a core mechanism in phobias and in trauma-related conditions such as PTSD. Treatments such as exposure and cognitive restructuring are built on these principles, which are discussed in the treatment sections. Anxiety disorders are the classic case where learned avoidance and threat appraisal interact.

Social determinants operate through similar pathways. Researchers have identified nine social factors and societal conditions as core determinants, including racial discrimination and social exclusion, adverse early life experiences, poor education, unemployment, poverty and income inequality, food insecurity, housing instability, the built environment, and limited access to health care. Specific associations have been reported: poverty is associated with higher rates of depression, racism is associated with higher rates of post-traumatic stress disorder (PTSD), and food insecurity is associated with depression and suicidal ideation. One proposed mechanism is that chronic stressors associated with poverty or racism cause brain inflammation and tissue damage that can lead to mental illness, though this remains a hypothesis. Unemployment has concrete consequences as well: when people develop schizophrenia and find themselves unemployed, they are likely to lose their insurance and have great difficulty accessing effective treatment for their condition. Urban living is associated with elevated rates in some groups. Point-prevalence studies of schizophrenia-spectrum disorders reported markedly elevated rates in incarcerated persons, homeless persons, and in areas with the highest levels of social fragmentation.

Family dynamics and attachment shape both the onset and course of disorder. Early caregiving relationships influence how children regulate emotion and approach close relationships, and insecure attachment patterns are often discussed as a vulnerability to later anxiety and depression. The relationship is bidirectional. Childhood trauma is linked to later disruption in the transition to adulthood, including failure to hold a job and social isolation, and those outcomes can in turn worsen symptoms. Disorder can likewise reduce work, relationships, and social participation, creating cycles that are difficult to disentangle causally. Most of the evidence is observational, so researchers continue to debate how much of the association reflects adversity itself and how much reflects shared genetic or family factors.

Diagnosis and Clinical Assessment

Assessment of mental disorder still rests mainly on the clinical interview. The clinician takes a history, asks about symptoms, their onset and duration, and their effect on daily functioning, and then decides whether the pattern meets diagnostic criteria. Because an unstructured conversation depends heavily on who is asking and how, researchers have built structured and semi-structured instruments to standardize it. The Structured Clinical Interview for DSM-5 (SCID-5) is a semistructured interview guide for making the major DSM-5 diagnoses. Instruments of this kind give clinicians a fixed route through the main DSM categories, with branching questions that tell the interviewer when a section can be skipped. Their reliability depends on training. Practitioners have been advised that maximizing reliability on the SCID requires extensive training in the diagnostic criteria and an emphasis on not taking shortcuts, meaning that the interviewer must elicit concrete descriptions of behavior to justify each criterion. Earlier reviews of the SCID for DSM-III-R concluded that the SCID has been found to yield highly reliable diagnoses for most axis I and axis II disorders. The version for DSM-5 has a thinner evidence base: studies examining the psychometric properties of the SCID-5 have not yet been published.

Rating scales and self-report questionnaires play a different role. Clinicians use them to measure how severe symptoms are, to track change over time, and to flag people who may need fuller assessment. A screening instrument is designed to be sensitive, so that few cases are missed, and it accepts a fair number of false positives. A diagnostic tool, by contrast, must be specific enough to support a formal classification, and a positive screen therefore normally leads to a clinical interview rather than to a diagnosis on its own. Dimensional scales are also used alongside categorical diagnosis, particularly where severity matters more than whether a threshold has been crossed.

Differential diagnosis is a prerequisite for any psychiatric label. Clinicians must first rule out general medical causes of symptoms, including thyroid dysfunction, neurological disease, and delirium, as well as intoxication, withdrawal, and adverse drug effects. They must then distinguish among disorders that look alike. Diagnostic overlap is common in practice. In one recent study based on case presentations, inter-rater reliability among medical doctors was modest, and the lowest accuracy was observed for cases depicting schizophrenia spectrum disorders, with schizophrenia cases frequently misclassified as OCD, personality disorder, or bipolar disorder. Such patterns show why a diagnosis made in one setting does not always transfer cleanly to another.

Comorbidity compounds this problem. In a large US health-records study, over 60% with an MDD diagnosis had co-occurring psychiatric diagnoses, especially neurodevelopmental and anxiety disorders. Estimates vary with the setting in which people are observed: in a German dataset of addiction treatment, the prevalence of comorbid diagnoses was considerably lower (4.6%) in outpatient settings than in inpatient settings (50.7%), which partly reflects where diagnostic assessment is structurally built into care. Population surveys suggest that about one in three adults with a mental disorder have a co-occurring mental disorder. Researchers have argued that such co-occurrence may point to shared etiologies, which would make categorical diagnoses partly artifacts of how symptoms are grouped, not clean natural boundaries.

Reliability, the degree to which different clinicians reach the same diagnosis, has been a central concern since DSM-III. Agreement is usually measured with the kappa statistic, which is the increment in observed agreement beyond that expected by chance. The DSM-III field trials reported that in phase one the overall kappa coefficient of agreement for axis I diagnoses of 281 adult patients was .78 for joint interviews and .66 for diagnoses made after separate interviews. The authors attributed the improvement to the systematic description of disorders and the inclusion of explicit criteria. Those trials also used ordinary clinical interviews rather than research-grade structured ones, a feature that made their results more representative of routine practice. Spitzer and Fleiss in the 1970s interpreted only kappa values above 0.7 as "satisfactory", a standard that the DSM-III trials also used. Later field trials were less favorable. At adult sites, schizophrenia was shown to have a pooled Kappa score of .46, which is down from the .76 and .81 Kappa scores found in the DSM-IV and DSM-III. Overall, the DSM-5 field trials reported low diagnostic reliability for many mental disorders, with kappa values comparable to those reported prior to the DSM-III field trials. Whether those declines reflect changes in criteria, sampling, or the sheer difficulty of rating psychological phenomena remains debated, and high agreement does not by itself establish that a diagnosis is valid.

Psychotherapeutic Treatments

Cognitive behavioral therapy

Cognitive behavioral therapy (CBT) has the largest evidence base of any psychological treatment for common disorders. It typically combines the identification and restructuring of distorted appraisals with behavioral experiments, scheduled activity, and graded exposure, delivered in a limited number of structured sessions. Its use is supported for depression, anxiety disorders, obsessive-compulsive disorder (where exposure and response prevention is the core component), and trauma-related conditions. The size of the benefit depends strongly on the comparison group. A 2022 meta-analysis of randomized trials with placebo or control conditions, published since 2017, found only small effects on target symptoms, with smaller effects in trials limited to PTSD. Older meta-analyses that compared CBT with waiting lists or usual care reported larger effects, and a 2025 systematic review of recent depression trials asked directly what the label "evidence-based" rests on. Guided internet-delivered CBT has also been studied in youth and in routine care, where it shows effects in uncontrolled designs but has less controlled evidence than face-to-face treatment.

Interpersonal, behavioral, and exposure-based treatments

Interpersonal therapy is a time-limited approach that focuses on current relationships, role transitions, grief, and interpersonal disputes, and it has been studied chiefly for depression, including perinatal depression. Behavioral activation is a simpler method that aims to increase contact with rewarding activities and reduce avoidance; in several trials it performed about as well as full CBT for depression. Exposure-based treatments involve repeated, planned contact with feared situations or traumatic memories. Prolonged exposure is used for PTSD, and exposure and response prevention is the standard psychological treatment for OCD. These are among the most robust psychological treatments for phobias and OCD.

Dialectical behavior therapy (DBT) was developed by Marsha Linehan for people with borderline personality disorder who had frequent suicidal and self-injurious behavior. It combines individual therapy, skills groups, telephone coaching, and therapist consultation, and it balances acceptance with change, hence the name. The first randomized trial, in the early 1990s, found fewer suicidal episodes, hospitalizations, and dropouts than with usual treatment. Later trials have produced more mixed results: a 2009 trial of 180 patients found DBT and a specialist-delivered general psychiatric management to be equally beneficial, and a noninferiority trial found that six months of DBT was comparable to twelve months on several outcomes. Systematic reviews generally find benefits for self-harm and suicidality, while changes in general psychopathology are usually moderate in size.

Psychodynamic, family, and group therapies

Psychodynamic therapies, which descend from psychoanalytic theory, work with unconscious conflict, defensive patterns, and the therapeutic relationship itself, and they are usually longer than CBT. Meta-analyses show moderate effects for depression and some anxiety conditions, and a few trials of long-term treatment suggest benefits for complex and personality-related problems. However, many trials are small, have weak controls, or lack long follow-up, and evidence for PTSD and OCD is limited. Family interventions have the strongest support in adolescent eating disorders and in psychosis, where family psychoeducation combined with medication reduces relapse. Group therapies are efficient and effective for depression, social anxiety, and substance use, but results vary by condition and facilitator training, and the evidence for group work in psychosis is weaker.

Third-wave approaches

Third-wave therapies emphasize changing one's relationship to thoughts and feelings rather than contesting their content. Acceptance and commitment therapy (ACT) aims at psychological flexibility and values-guided action. Mindfulness-based cognitive therapy (MBCT), adapted from mindfulness-based stress reduction, was designed to prevent relapse in recurrent depression and has been shown to reduce relapse in people with several prior episodes. Evidence for mindfulness-based and acceptance-based programs in anxiety, chronic pain, and general stress is more heterogeneous, and many trials are small or compare against weakly matched controls.

Common factors and the comparative debate

Since Saul Rosenzweig's 1936 proposal, the so-called dodo bird verdict has held that different bona fide psychotherapies often produce similar outcomes, which points to shared ingredients such as the therapeutic alliance, expectancy, and the therapist's empathy. A widely cited 1992 estimate attributed nearly 40% of improvement to client and therapist factors. A large meta-analysis by Wampold and colleagues in 1997 found broad equivalence, although cognitive-behavioral treatments were somewhat more effective on primary outcomes. Critics, including Hunsley and Di Giulio in 2002, argued that the equivalence claim is overstated, that many comparative trials lack the power to detect differences, and that disorder-specific techniques such as exposure matter. The current consensus is therefore that the alliance and nonspecific factors explain much of the variance across therapies, while specific techniques remain important for particular conditions, and that the causal role of any single common factor has not been firmly established.

Pharmacological and Somatic Treatments

Antidepressants

Selective serotonin reuptake inhibitors (SSRIs) became a mainstay of treatment after fluoxetine reached the United States in 1988. They block the serotonin transporter, so serotonin stays longer in the synaptic cleft, but symptom relief usually takes several weeks. That lag is why much research has focused on slower downstream changes, such as altered gene expression, neurotrophic signaling and neuroplasticity, rather than the immediate rise in neurotransmitter levels alone. Other classes include serotonin–norepinephrine reuptake inhibitors, bupropion, mirtazapine and tricyclic antidepressants. Monoamine oxidase inhibitors are usually reserved for selected patients because of dietary and drug interactions.

SSRI side effects are mostly gastrointestinal (nausea, diarrhea), sleep-related (insomnia or daytime sedation), and sexual (reduced libido, delayed orgasm or ejaculation), with sexual dysfunction reported by a large share of users depending on how it is measured. Paroxetine is more associated with weight gain. Several regulators carry a warning about increased suicidal thinking in young people, while evidence for an increase in adults is weaker, so the risk of untreated illness must be weighed. Serotonin syndrome is rare but serious, especially when serotonergic drugs are combined.

Antipsychotics

First-generation (typical) antipsychotics, such as chlorpromazine, introduced in the early 1950s, and haloperidol, act mainly by blocking dopamine D2 receptors. Their motor side effects include parkinsonism, akathisia and acute dystonia, and long-term use can cause tardive dyskinesia, which is often irreversible. Second-generation (atypical) agents, including risperidone, olanzapine, quetiapine and aripiprazole, add serotonergic actions and generally produce fewer movement disorders but more weight gain, insulin resistance, dyslipidemia and sedation, so routine metabolic monitoring is standard. Clozapine, introduced in the 1970s, is the most effective option for treatment-resistant schizophrenia, but it requires regular blood tests because of the risk of agranulocytosis, and it is also associated with seizures and myocarditis. Long-acting injectable formulations are used to address non-adherence.

Lithium, Anticonvulsants and Anxiolytics

Lithium, whose antimanic effect was described by John Cade in 1949, remains a reference mood stabilizer for bipolar disorder, with some of the strongest evidence of any long-term treatment for reducing suicide risk in mood disorders. Its narrow therapeutic index demands blood-level monitoring, and long-term use can affect kidney and thyroid function and cause tremor and weight gain. Valproate, lamotrigine and some second-generation antipsychotics serve as alternatives or add-ons, with lamotrigine favored mainly for preventing depressive recurrence.

Benzodiazepines act on GABA-A receptors and relieve acute anxiety and panic quickly. However, tolerance, dependence, withdrawal, cognitive impairment and falls in older adults limit long-term use. Current guidance therefore usually places SSRIs, serotonin–norepinephrine reuptake inhibitors and psychological treatment first for anxiety disorders, with benzodiazepines restricted to short-term or crisis use. Buspirone is a non-benzodiazepine option for some patients.

Neuromodulation

Electroconvulsive therapy (ECT), introduced in 1938 by Cerletti and Bini in Italy, is given under general anesthesia with muscle relaxation, and a brief electrical current induces a generalized seizure. Its indications include severe or psychotic depression, catatonia, high suicide risk, life-threatening refusal of food and fluids, and treatment-resistant depression, where it is distinguished by speed and effectiveness. The main adverse effects are confusion and memory disturbance, which are usually transient but can be prolonged. Ultrabrief pulse stimulation reduces cognitive effects, and because relapse after an acute course is common, continuation or maintenance treatment is often used.

Repetitive transcranial magnetic stimulation (rTMS) delivers magnetic pulses, usually to the dorsolateral prefrontal cortex, without anesthesia or seizure induction. It was cleared for major depression in the United States in 2008. A course typically involves daily sessions over several weeks, and the common side effects are scalp discomfort and headache, while seizures are rare. Accelerated protocols such as theta-burst stimulation shorten treatment time. Vagus nerve stimulation and deep brain stimulation are used in severe or refractory cases, and their evidence remains more limited.

Placebo Response and Trial Methodology

Placebo response is a central problem in psychopharmacology. In adult antidepressant trials, the mean placebo response has been about 31% against roughly 50% for medication, and it has risen over several decades. The average advantage of drug over placebo on the Hamilton Rating Scale for Depression fell from about 6 points in 1982 to about 3 points in 2008. Many randomized trials submitted to the US Food and Drug Administration have failed to show that approved antidepressants outperform placebo. Proposed contributors include patient expectancy, the intensity of therapeutic contact, and the natural fluctuation of depression. Design responses include placebo lead-in phases, excluding likely placebo responders, and sequential parallel comparison designs. Critics argue that such reports may discourage patients from seeking treatment, while meta-analyses suggest that high placebo response accounts for much of the variability in drug–placebo differences. The same issues affect the interpretation of evidence for somatic treatments more broadly.

Treatment Selection, Combination and Shared Decision-Making

Choice of treatment depends on diagnosis, severity, suicide risk, previous response, side-effect tolerance, physical comorbidity, age, pregnancy and cost. Stepped strategies are common. In the US STAR*D trial, roughly a third of participants reached remission on a first antidepressant, and cumulative remission rose to about two-thirds after up to four sequential steps, though later steps yielded smaller gains. Clinicians also use augmentation, such as adding an antipsychotic (aripiprazole has regulatory approval as an adjunct for major depression) or lithium, and combining medication with psychotherapy often improves outcomes in moderate to severe or chronic depression. In bipolar disorder, combination of a mood stabilizer and an antipsychotic is widely used during acute mania.

Shared decision-making means presenting realistic benefits, uncertainty, side effects and alternatives, and aligning the choice with the patient's values and priorities. Decision aids and structured informed consent processes support this, and consent requirements are particularly strict for ECT and for any treatment given without the patient's agreement. Pharmacogenomic testing for drug selection has been promoted, but its evidence for routine use is still limited.

Organization of Care

Organization of care concerns how mental health services are governed, financed, staffed, and located. Much of the global picture comes from the WHO Mental Health Atlas, a periodic survey first run in 2001. The 2024 edition, released in September 2025, drew on data from 144 countries and tracked progress toward the targets of the WHO Comprehensive Mental Health Action Plan 2013–2030. Its overall message is that policy has advanced further than funding, workforce, and service capacity.

From long-stay hospitals to community services

For most of the nineteenth and twentieth centuries, large public psychiatric hospitals were the main setting for severe mental illness. In the United States, the number of beds in state and county psychiatric hospitals fell by more than 90 per cent between 1955 and 2005. The shift was driven partly by antipsychotic drugs from the 1950s, which made outpatient management feasible, and partly by civil rights critiques of institutional abuse and neglect. President John F. Kennedy signed the Community Mental Health Act in 1963, which called for a national network of roughly 1,500 community mental health centres. Hospital discharges, however, outpaced the capacity of these centres. Many former patients ended up homeless, in cheap single-room housing, or in nursing homes, board-and-care homes, and jails. Researchers describe this as a revolving door and as "transinstitutionalization", in which the population was moved rather than adequately cared for.

Similar reforms in Western Europe, including Italy's 1978 law that closed its asylums, and in Latin America, including Brazil's community-based network, gave deinstitutionalization a broader meaning as a reorientation toward local, rights-based care. The process remains incomplete. Recent WHO reporting notes that inpatient care still relies heavily on psychiatric hospitals, with nearly half of admissions involuntary and more than 20 per cent of stays lasting over a year. Many systems keep long-stay hospitals organizationally separate from general health services.

Integration with primary and general care

A second strand of reform places mental health within primary care and general hospitals rather than in specialist silos. WHO reports that integration into primary care is advancing, and the 2024 Atlas added indicators on telehealth, physical health, and community-based care. A central tool is the WHO Mental Health Gap Action Programme (mhGAP), whose Intervention Guide trains non-specialist staff, such as general practitioners and nurses, to recognize and manage priority conditions. Its implementation has been studied in several former Soviet republics, including Ukraine, Armenia, Georgia, and the Kyrgyz Republic. Task-sharing models of this kind rely on lay health workers. Randomized trials in India and Zimbabwe found that lay counsellors could deliver effective psychological support for depression, and the Zimbabwean Friendship Bench programme is a widely cited example of a low-cost, community-delivered model.

Workforce distribution

Human resources are the clearest source of inequality. Data cited from the 2018 Atlas show an average of 11.9 psychiatrists per 100,000 people in high-income countries, compared with fewer than 0.1 in low-income countries. For nurses working in mental health, the comparable figures were 23.5 and 0.3. Commentary based on the 2024 Atlas describes roughly one psychiatrist per million people in low-income countries, with high-income countries having about seventy times as many. Child and adolescent psychiatrists are scarcer still. These gaps are the main reason non-specialist task-sharing has become a policy priority in low- and middle-income settings.

Financing and the treatment gap

Median government spending on mental health was about 2 per cent of total health budgets in the 2024 Atlas, unchanged since 2017. Per-person spending ranged from roughly US$65 in high-income countries to US$0.04 in low-income countries. In about half of responding countries, patients paid less than 5 per cent of the cost of inpatient and outpatient care and psychotropic medication. In other countries, out-of-pocket payments made up most of the cost of treatment, which can push people away from care altogether.

The treatment gap is the proportion of people with a condition who receive no care or inadequate care. WHO's World Mental Health Surveys found that 76 to 85 per cent of people with severe disorders in low- and middle-income countries received no treatment in the previous 12 months, compared with 36 to 50 per cent in high-income countries. A separate Lancet Psychiatry estimate suggested that only about 9 per cent of people with major depressive disorder worldwide receive minimally adequate treatment, with the figure near 27 per cent in high-income countries and around 2 per cent in sub-Saharan Africa. Such estimates depend on survey design and on definitions of adequate care, so they should be compared with caution.

National plans, laws, and data systems

Most countries now have a mental health policy or plan, and about 61 per cent reported publishing or updating one since the previous Atlas. However, the Atlas treats a plan as implemented only when it meets at least two of three conditions: necessary human resources are estimated and allocated, necessary financial resources are estimated and allocated, and indicators or targets are specified. Legislation is assessed alongside plans, and WHO reports that more countries are aligning their policies with human rights standards, including the UN Convention on the Rights of Persons with Disabilities. Data systems remain weak: about 76 per cent of countries kept records of outpatient users, but only about 54 per cent collected data on treatment outcomes. Without such data, it is difficult to judge whether plans are changing the quality of care that people actually receive.

Sources:

• Mental Health Atlas 2024 (WHO), 持续 — https://www.who.int/publications/i/item/9789240114487
• Over a billion people living with mental health conditions – services require urgent scale-up (WHO news) — https://www.who.int/news/item/02-09-2025-over-a-billion-people-living-with-mental-health-conditions-services-require-urgent-scale-up
• Mental Health Atlas 2024 (WHO IRIS) — https://iris.who.int/server/api/core/bitstreams/5897b3c7-2848-47a7-ba22-0a7902342a81/content
• Mental Health Atlas 2024 summary (ruralindiaonline) — https://ruralindiaonline.org/en/library/resource/mental-health-atlas-2024/
• Mental health care is scarce everywhere — but in poor countries, it barely exists (Our World in Data) — https://ourworldindata.org/data-insights/mental-health-care-is-scarce-everywhere-but-in-poor-countries-it-barely-exists
• Mental health service coverage and gaps among adults in Europe: a systematic review (ScienceDirect) — https://www.sciencedirect.com/science/article/pii/S2666776225002509
• The mhGAP Intervention Guide pre-service training study (PMC) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325034/
• The Implementation of the WHO mhGAP-IG in Ukraine, Armenia, Georgia and Kyrgyz Republic (PMC) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122418/
• Psychiatric Institutionalization and Deinstitutionalization (Congressional Research Service) — https://www.congress.gov/crs-product/IF10870
• Cycles of reform in the history of psychosis treatment in the United States (PMC) — https://pmc.ncbi.nlm.nih.gov/articles/PMC10302760/
• Transition of Mental Health Services from Institutional to Community-Based Care Abroad (PMC) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12294201/
• Deinstitutionalisation – an overview (ScienceDirect Topics) — https://www.sciencedirect.com/topics/medicine-and-dentistry/deinstitutionalisation

Prevention and Early Intervention

Prevention models

Prevention in mental health is often organised with a model borrowed from Gordon's 1983 scheme, rather than the older primary, secondary and tertiary categories. Under this scheme, a universal intervention is offered to a whole population regardless of individual risk, such as a programme that promotes healthy, substance-free living. A selective intervention is directed at subgroups whose risk of illness is above average, for example migrants or people exposed to disaster or destitution. An indicated intervention is aimed at individuals who already show a risk marker or early symptoms, such as a family history of psychiatric illness or subclinical symptoms. The Institute of Medicine's 1994 committee adapted this framework for mental disorders, and critics note that the older and newer systems are sometimes blended inconsistently. Gordon also argued that indicated prevention differs from treatment because it acts on an abnormality before the disorder is clinically established, which raises distinct ethical questions about labelling people who are not yet ill.

In psychiatry, the three levels are illustrated by social and emotional curricula in elementary schools (universal), group-based psychotherapy for children of parents with depression (selective), and efforts to identify young people at clinical high risk of schizophrenia (indicated). The last category has a notable limitation: the rate of false positives in high-risk identification remains high. Evidence for universal approaches is comparatively thin, which has led some researchers to argue for combining universal and targeted strategies.

School-based and parenting programmes

School-based programmes are a major route for reaching children and adolescents, because schools reach most young people and allow repeated contact. Universal programmes in schools can improve mental health literacy across a student body and may normalise help-seeking, while also avoiding the stigma of labelling students as at-risk. Selective and indicated programmes, by contrast, depend on identifying the right students, which is administratively difficult and can carry stigma. Parenting interventions follow a similar tiered logic. Targeted parenting programmes may be more cost-effective, but screening for children who are at risk or showing early symptoms relies heavily on parents' ability to recognise problems. Reviews also find that a programme can fail at one prevention level for a given outcome while succeeding at another, so effectiveness should be judged outcome by outcome.

Early intervention for first-episode psychosis

The rationale for early intervention rests on the duration of untreated psychosis (DUP), the interval between the onset of psychotic symptoms and the start of effective treatment. Longer DUP has been associated with poorer functioning, more severe positive and negative symptoms, and lower chances of remission, although some researchers question whether the link to psychosocial functioning is partly an artefact. Early intervention in psychosis services typically work with patients during the first three years after onset, using explicit admission criteria, small caseloads, antipsychotic medication, and psychosocial care including family involvement and supported employment or education. A 2024 meta-analysis of early intervention studies found that these services improved quality of life, employment rates and negative symptoms, whereas strategies aimed at detection alone produced only limited reductions in DUP. Evidence of benefit from specialised programmes has been more consistent than evidence that particular early-detection campaigns shorten DUP. In many countries, the median DUP has been reported as several months or more, and in some US community settings it has been measured at well over a year.

Suicide prevention

Suicide prevention includes universal population measures, targeted support for people at risk, and clinical interventions in health services. Restricting access to lethal means is among the best-supported strategies. The WHO describes it as a universal evidence-based intervention, implemented through measures such as banning highly hazardous pesticides, restricting firearms, installing barriers at known sites, and limiting ligature points. The rationale is that many suicidal crises are brief and ambivalent, so delaying access to a method can allow a crisis to pass. Reviews of natural experiments report declines in national suicide rates of substantial size following such restrictions, although a systematic overview of primary prevention found that means restriction was the only single intervention with some evidence of efficacy in the general population. Substitution to other methods is a concern, but evidence suggests that it is partial and slower. In health services, lethal means safety counselling is used in risk assessment, particularly in paediatric care, but implementation remains inconsistent.

Public policy measures

Population-level risk reduction also operates through policies outside the health sector. Regulation of alcohol availability and pricing, violence prevention, and income support are frequently cited because they address social determinants that increase the risk of mental disorders and related harms. Such measures are usually evaluated through population-level studies and natural experiments rather than randomised trials, which makes causal attribution difficult. For this reason, policy approaches are generally presented as complements to clinical and school-based prevention rather than as substitutes for them.

Stigma, Discrimination, and Human Rights

Public, self, and structural stigma

Research on mental health usually separates stigma into three levels. Public stigma is the prejudice held by the wider population, including stereotypes and social distance. Self-stigma, sometimes called internalized stigma, occurs when a person with a diagnosis absorbs those attitudes and applies them to themselves. Structural stigma is built into laws, institutions, and policies that limit what people with diagnoses can do. Stigma and discrimination contravene basic human rights and have detrimental effects on people with mental health conditions by exacerbating marginalization and social exclusion. A synthesis of over 260 systematic reviews on stigma reduction has been used to map the global evidence on how these forms can be reduced.

The three levels affect help-seeking in different ways. A widespread belief that people with mental health conditions are dangerous is, for the vast majority, quite the opposite of the evidence. Such myths can discourage people from asking for help, deepen hopelessness, and make relationships, schooling, and work harder to sustain, and in serious cases are linked to shorter lives (Stigma and discrimination fuel these myths and can prevent people from seeking help, increase hopelessness, make it harder to pursue relationships, education and employment, and even decrease life expectancy.). Among students, the fear of being judged is a barrier to school-based services, and adolescents often name it as their main reason for avoiding them (For students of all ages, anticipated stigma is a barrier to seeking school-based mental health services. In the K12 setting, adolescents report that fear of being stigmatized was the most). Self-stigma works in a similar way, since a person who expects rejection may conceal symptoms or decline treatment before anyone has treated them badly.

Discrimination in education, employment, housing, and insurance

Discrimination is the behavioural counterpart of stigma. Research draws on WHO-related reviews that describe a range of harms, from everyday avoidance to clear rights violations, including limits on education, work, marriage, and parenthood (A variety of personal and social discriminatory acts arise from mental health stigma, from interpersonal avoidance to human rights violations, including restrictions on rights to education, work, marriage, and reproduction). A 2024 national survey in Australia asked more than 6,000 adults about discrimination; among respondents who reported a mental health problem or high psychological distress, questions covered family, workplaces, and health services, which shows that the problem reaches beyond formal institutions (Online surveys were completed by 6032 members of the general Australian community aged 18 years and over. Those who reported a mental health problem or scored high on the Kessler 6 measure of psychological distress (n = 2613) were asked about the past 12-month frequency and impact of their experiences of discrimination in a broad range of settings, including family, friends, workplaces and health services.).

Responses in housing, employment, insurance, and education have generally taken the form of anti-discrimination statutes, reasonable-accommodation duties, and rules limiting how insurers and employers may use diagnostic information. The scope, exceptions, and enforcement of these rules differ widely between jurisdictions, and evidence on how well they work in practice is thinner than the legal framework itself. Legislation and judicial review are often the routes through which individuals test whether these protections apply.

The UN Convention on the Rights of Persons with Disabilities

The United Nations Convention on the Rights of Persons with Disabilities (CRPD) is the most consequential human rights treaty for mental health services. Its provisions on equal recognition before the law (Article 12), liberty (Article 14), and physical and mental integrity (Article 17) apply directly to psychiatric practice (The CRPD challenges traditional mental health legislation as it states that ‘persons with disabilities have the right to equal recognition before the law’ (article 12); ‘the existence of a disability shall in no case justify a deprivation of liberty’ (article 14); and ‘every person with disability has a right to respect for his or her physical and mental integrity on an equal basis with others’ (article 17)).

The treaty's text is less categorical than its interpreters. Article 12 is widely read as shifting from substitute decision-making toward supported decision-making, and the CRPD Committee's 2014 General Comment 1 took this further. The committee interprets the CRPD as prohibiting involuntary treatment under any circumstances and calls upon States Parties to abolish all substitute decision-making regimes. The committee's reading of Article 14 is similar, treating involuntary hospitalization as incompatible with the Convention. Psychiatric bodies and some clinicians disagree. Advocacy groups push for the elimination of involuntary treatment in favour of alternative measures, arguing that it results from inadequate resources, while psychiatric associations highlight ethical concerns about withholding care and emphasize risks to service users and others. Some service-user organizations support the committee's position, but this is not universal, and family members often hold different views (Although many mental health service users' organizations support the prohibition of involuntary admission and treatment, there are indicators showing that this view is not shared by all people with mental disorders nor by the majority of family members.). Legal commentators have also argued that existing mental health statutes conflict with the Convention; the Mental Health Act in England and Wales is cited in this regard (Conventional mental health legislation, such as the Mental Health Act (England and Wales) appears to violate, for example, Article 4 ('no discrimination of any kind on the basis of disability'), Article 12 and Article 14). Proposals for reform include models that use decision-making capacity as the criterion for compulsory treatment, but these models remain contested.

Involuntary treatment, restraint, and seclusion

Involuntary admission, compulsory medication, restraint, and seclusion are the most direct points at which human rights law and clinical practice meet. Clinicians often justify them as protection against imminent harm to the patient or others, and in some countries a court or tribunal must authorize them. Critics argue that these practices are traumatic, that they can undermine trust and future help-seeking, and that they are disproportionately applied to some groups. It has called attention to the fact that, for many people with mental disorders and psychosocial disabilities, involuntary admission and treatment may be a very painful and traumatic experience. Restraint and seclusion have drawn particular criticism from UN human rights bodies, which question whether they can be justified outside narrow emergency conditions. Procedural safeguards, including independent review, time limits, and the right to appeal, are widely regarded as the minimum standard in regimes that still permit coercion.

Anti-stigma campaigns and their evidence

Anti-stigma efforts include mass media campaigns, school education, workplace training, and structured contact between people with and without diagnoses. The best-known example is the contact-based approach, which assumes that personal contact with people who have lived experience reduces prejudice. Systematic reviews generally find some benefit. One review of 62 randomised controlled trials of contact interventions, educational interventions, mixed contact and education, family psychoeducation programs, and hallucination simulations reported small-to-moderate reductions in stigmatizing attitudes, and contact-based interventions delivered a small-to-moderate reduction in stigma and were better than education interventions for reducing stigma in adults. Effect sizes vary, and meta-analyses of contact interventions have reported effects of roughly d = .282 to d = .470.

The evidence is contested. Reanalysis of one influential meta-analysis suggested that five studies were potentially missing, reducing the estimated effect size from a Cohen's d of 0.39 to 0.24, which points to publication bias. Critics argue that the evidence on the effectiveness of contact-based interventions is weak. Durability is a further concern. Some trials show short-term changes that fade within weeks, and in youth the results have been not consistent. Brief interventions may also be too short to matter, since one digital contact study noted that its "dose" of approximately 8 minutes may have limited its effect, and other interventions typically last much longer. Newer work is trying to identify which components, such as reduced anxiety about contact or increased empathy, drive change (A meta-analysis of over 500 studies confirmed that contact can diminish prejudice through resulting in reduced anxiety about contact, and increased empathy and perspective taking.). Evaluations of anti-stigma work also tend to measure attitudes and intentions, not changes in actual discrimination, so the link between campaigns and outcomes such as employment or access to care remains largely unproven.

Legal and Forensic Dimensions

Criminal responsibility and the insanity defense

Law asks a different question from clinical psychiatry. A diagnosis does not settle whether a person is criminally responsible for an act, and courts have built separate tests for that purpose. The modern common-law tradition begins with the 1843 case of Daniel M'Naghten, who shot and killed the secretary of the British prime minister while believing that he was being persecuted. The court acquitted M'Naghten "by reason of insanity," and he was placed in a mental institution for the rest of his life. Public anger over the verdict led the Crown to demand a stricter standard, and the judges' responses established the specific test to be applied by a jury in an insanity case. Under this right-wrong formulation, a defendant was not responsible if, at the time of the act, he did not understand its nature or that it was wrong.

In 1954 the U.S. Court of Appeals for the D.C. Circuit adopted the Durham or "product" test, under which an unlawful act that was the product of mental disease or defect was not criminally punishable. The test never received wide acceptance in the United States; thirty states and five federal circuits examined the test and ultimately rejected it. The same court abandoned it in 1972 and adopted the American Law Institute standard instead. The Model Penal Code formulation asks whether a defendant, because of mental disease or defect, lacked substantial capacity to appreciate the criminality of conduct or to conform it to law. It replaces the absolute knowledge demanded by M'Naghten with a substantial-incapacity threshold, and it also requires a recognized mental disorder. By 1982 all federal courts and a majority of state courts had adopted the ALI test. After John Hinckley was acquitted in 1982 for the attempted assassination of President Reagan, Congress passed the Insanity Defense Reform Act of 1984, which placed the burden of proof on the defendant and removed the volitional prong from federal law. Within the United States, the laws of a particular state determine which test applies.

Competence to stand trial

Competence to stand trial is a distinct question: whether a defendant can take part in the prosecution at all. It is the most frequently raised mental health issue in American criminal courts. The leading U.S. standard comes from Dusky v. United States (1960). Dusky had schizophrenia, and the trial court had found him fit largely because he was oriented to time and place. The Supreme Court held that this was insufficient. The test asks whether a defendant can consult with counsel with a reasonable degree of rational understanding and has a rational as well as factual grasp of the proceedings. The Court emphasized that a brief mental status exam was insufficient to pass constitutional muster. The Court later confirmed the framework in Godinez v. Moran (1993). Whether most state standards truly require rational understanding is debated, since many do not explicitly do so. A psychiatric diagnosis alone does not decide the question. Many people with serious mental illness are competent to stand trial, and some people without a formal diagnosis are not. The competence threshold also differs by context: the standard for competency to stand trial must be lower than the standard for competency to represent oneself.

Civil commitment and involuntary treatment

Civil commitment concerns detention for treatment rather than punishment, and its criteria have shifted over time. The standards for civil commitment shifted to a focus on dangerousness in the 1960s, and California's Lanterman-Petris-Short Act became the model for many later statutes. That act specifies three "dangerousness" criteria: danger to self, danger to others, and grave disability. In virtually all states, dangerousness to self or others is an explicit criterion, and in most states grave disability is also included as an alternative to dangerousness. The need for treatment is included in nearly every state, either explicitly as its own criterion or as a component of the statute's definition of mental illness. Need-for-treatment provisions are controversial. Their supporters argue that a dangerousness-only standard leads clinicians to neglect severely ill patients who pose less immediate risk, and under some statutes an involuntary treatment order may be issued when an individual lacks insight into his or her illness and cannot make an informed decision about psychiatric care.

Procedural safeguards are central. A state must prove by at least clear and convincing evidence that a person, as a result of mental illness, poses a danger to self or others or is unable to provide basic self-care. In O'Connor v. Donaldson (1975), the Supreme Court held that a state cannot confine a nondangerous person who can survive safely in freedom. The Court did not define how much dangerousness is required, so that threshold has been set largely by state courts and legislatures. Courts also require case-specific reasoning: one North Carolina ruling held that the trial court must make findings about the individual's past and current symptoms and link them to the risk of dangerousness. Hearings and time limits apply as well, since states permit involuntary treatment for just a few days before a judge must review the matter.

Decision-making capacity, guardianship, and consent

Capacity is assessed decision by decision rather than as a global status. In England and Wales, the Mental Capacity Act 2005 presumes that adults have capacity, requires that every reasonable effort be made to support them, and asks whether a person can understand, retain, and weigh information and communicate a choice. A psychiatric diagnosis does not by itself remove capacity. Guardianship arrangements, which once often transferred全部 decision-making power to a guardian, are increasingly being replaced by narrower or supported arrangements, a shift linked to Article 12 of the UN Convention on the Rights of Persons with Disabilities. Capacity underpins how an evaluator should determine whether a waiver is competent or the person has the relevant decision-making capacity, which in turn governs whether consent to treatment is valid, as discussed under informed consent.

Legal definitions across jurisdictions

Legal definitions of mental disorder are statutory and do not track clinical manuals such as the DSM or ICD. England and Wales' Mental Health Act 1983, as amended in 2007, defines mental disorder broadly as any disorder or disability of the mind, but excludes learning disability alone unless it is accompanied by abnormally aggressive or seriously irresponsible conduct. Germany's penal code combines a list of pathological conditions with a functional test of whether the offender could appreciate wrongdoing or act on that appreciation. Many national systems also tie civil commitment to dangerousness: Austria, Belgium, Germany, Israel, the Netherlands, Northern Ireland, the Republic of Ireland, Russia, Taiwan, Canada, and the United States have adopted commitment criteria based on the presumed danger of the defendant to self or to others. The result is that a clinical diagnosis is often necessary but never sufficient. A legal decision requires a further judgment about responsibility, functional capacity, or risk, and that judgment is ultimately made by courts applying legislation and common-law precedent, often subject to judicial review. The gap between diagnostic and legal categories is one reason forensic evaluation has become a specialty of its own, forensic psychiatry.

Cultural Variation and Cross-Cultural Psychiatry

For much of the twentieth century, Western psychiatry grouped distress patterns that seemed confined to particular societies under the heading of culture-bound syndromes. DSM-5 reduced the number of such entries in its glossary from 25 in DSM-IV-TR to only 9. The category remained contested. Anthropologists have tended to stress relativistic, culture-specific dimensions of these syndromes, while physicians have tended to stress universal and neuropsychological ones. The most frequently raised objection is that their symptoms often overlap with those of established psychiatric disorders. The dhat syndrome, a semen-loss complaint described in South Asia, has been the most disputed case, and later research suggested that it is not as culture-bound as previously thought. Kleinman's critique took the opposite line: non-Western disorders are not merely culturally specific variations of Western disorders.

DSM-5 responded by replacing the older label with the framework of cultural concepts of distress, which was introduced partly in response to the critique of the previous notion of culture-bounded syndromes. The framework has three constructs. A cultural syndrome is clusters of symptoms and attributions that tend to co-occur among individuals in specific cultural groups, while a cultural idiom of distress is a way of expressing suffering that may not involve specific symptoms or syndromes. A cultural explanation supplies the culturally recognized cause or meaning attached to symptoms. The glossary's entries include ataque de nervios, khyâl cap, and kufungisisa, among others. The concepts do not map neatly onto diagnoses: the correspondence between a cultural concept and a diagnostic entity is more probably one-to-many, and the severity it denotes may range from symptoms that meet no disorder criteria to conditions that do. The same term can also refer to several concepts and may shift over time. The framework also works in both directions. For Western clinicians, major depressive disorder can be considered a syndrome, but depression can also be considered an idiom of distress, since Westerners commonly talk of feeling depressed in everyday life.

The main clinical tool for applying this material is the Cultural Formulation Interview (CFI). Its origins lie in the Outline for Cultural Formulation of DSM-IV, which the DSM-5 work group refined into the Cultural Formulation Interview (CFI), with patient and informant versions and 12 supplementary modules. The core instrument has 16 items, and it asks the clinician to explore the patient's own account of the problem, the cultural identities and social supports involved, and the cultural factors bearing on the relationship with the clinician. The CFI is not a test of how well someone knows their culture. It focuses on how far participation in a culture shapes health. Its designers also warned against reading a patient's background as a set of stereotyped norms, since knowing a patient's cultural membership does not justify applying the norms of that one culture to this individual in a stereotyped fashion. Evidence on use remains limited. A Swedish outpatient study found that patients and clinicians found the CFI to be a feasible, acceptable, and clinically useful assessment tool. The rationale is that if cultural factors are not properly assessed, patients may receive an incorrect diagnosis, or the severity of their condition may be misjudged.

Cross-cultural comparisons of prevalence and diagnosis raise a methodological problem. Two models have shaped the debate. One, the pathogenic-pathoplastic model, holds that underlying causes of mental disorders are the same globally, while their expressions vary due to cultural factors. The other holds that some syndromes are distinct conditions without direct Western equivalents. Somatic expression is a common example of the first pattern. Hwa-byung, a Korean concept, involves a wide variety of physical and emotional symptoms, which patients attribute to physical causes, while they consciously ignore the mental aspects of their situation. When prevalence rates differ between countries, a real difference in disorder must be separated from artifacts. These include translation of questionnaires, the wording of diagnostic items, sampling frames, differences in help-seeking and stigma, and the expectations of clinicians who may be unfamiliar with local idioms. Surveys built on Western diagnostic criteria can therefore record differences in expression as differences in prevalence.

Indigenous and traditional healing systems pose a related challenge. Critics have argued that psychiatrists and many anthropologist observers ignored existing indigenous health-care systems, idioms of distress and the therapeutic interventions used by these populations. Many traditional systems, such as curanderismo in Latin America or Ayurveda in South Asia, have their own explanatory models of illness, healers, and therapeutic practices. Their relationship with biomedical psychiatry varies from parallel use and referral to partial integration, and the interaction raises questions about evidence, safety, and respect for patients' own explanations of their suffering.

Controversies and Debates

Debate over whether psychiatric diagnoses are valid starts with a basic question: do disorders correspond to natural kinds, meaning discrete types that exist independently of how clinicians group them? Most mental disorders lack an established cause or pathophysiology, so their boundaries rest on clusters of symptoms, course, and treatment response. Critics argue that categories such as major depression or schizophrenia are provisional conventions that have been reified, while defenders maintain that syndromes that predict outcomes and respond to treatment are useful even without a biological marker. The disagreement is not resolved by the evidence now available, and it shapes how each side reads every other controversy below.

The medicalization of ordinary experience is most visible in the case of grief. The DSM-5 removed the bereavement exclusion, which had prevented a diagnosis of major depressive disorder within roughly two months of a loss, a period that the Task Force regarded as somewhat arbitrary. Critics have argued that removal of the bereavement exclusion will "medicalize" ordinary grief and encourage over-prescription of antidepressants. Supporters answered that there have never been any adequately controlled, clinical studies showing that major depressive syndromes following bereavement differ in nature, course, or outcome, and that severe depression carries a substantial suicide risk. The DSM-5-TR later added prolonged grief disorder as a separate condition. Similar threshold disputes arise around shyness, social anxiety, and normal variation in mood and behavior, where the question is less whether a symptom exists than where distress and impairment begin.

Diagnostic expansion across editions is a second axis of dispute. Counts vary with how subtypes and specifiers are tallied, but the number of recognized categories has grown considerably since the first edition. One review notes that the number of disorders has doubled and tripled since the first edition of the DSM. Counts for the most recent revisions also differ by method: one analysis reports that the number of mental health disorders in DSM-5 has reduced from 172 in DSM-IV to 157, but also includes 15 new disorders. Critics such as Allen Frances argued that loosened criteria and proposed high-prevalence conditions, including mild neurocognitive disorder and disruptive mood dysregulation disorder, would drive rates of diagnosis upward; a later meta-analysis set out to test whether diagnostic stringency had in fact declined across editions. Defenders often describe added categories as refinements that identify previously underdiagnosed people. The childhood irritability example illustrates the dispute: the DSM-5 added disruptive mood dysregulation disorder partly to address what many believed was the inappropriate diagnosis of Bipolar Disorder among children with irritability and conduct problems.

Financial conflicts of interest form a third area of concern. A 2006 study by Cosgrove and colleagues examined 170 panel members who contributed to the diagnostic criteria produced for the DSM-IV and the DSM-IV-TR and concluded that the connections are especially strong in those diagnostic areas where drugs are the first line of treatment for mental disorders. A follow-up comparison reported that 57% of DSM-IV task force members had ties to industry, against 69% of the DSM-5 task force members, and the authors concluded that disclosure rules had not reduced these conflicts. In a separate analysis of new DSM-5 diagnoses, 61% of the DSM Task Force members and 27% of Work Group members reported FCOI to the trial drug manufacturers. Supporters of the APA process note that the existence of ties does not by itself establish that criteria were biased, and that the evidence on how such ties affect specific decisions is limited.

Finally, the anti-psychiatry tradition, associated with Thomas Szasz's argument in the early 1960s that mental illness is a myth or metaphor for problems in living, with R. D. Laing's work on the family and experience of psychosis, and with Michel Foucault's historical account of psychiatry as an instrument of social control, continues to shape public debate. Its arguments are now often heard in popular discussions of antidepressants, the "chemical imbalance" explanation, and coercive treatment. Some of its concerns, particularly about coercion and the rights of people with psychiatric diagnoses, have been absorbed into mainstream human rights and policy frameworks, while its more radical claim that mental disorders do not exist remains contested within psychiatry and psychology.

Research Frontiers and Future Directions

Dimensional and transdiagnostic frameworks

A major research goal is to move beyond categorical diagnoses. The Hierarchical Taxonomy of Psychopathology (HiTOP), built by an international consortium of nosologists, arranges symptoms, maladaptive traits and behaviors into a hierarchy, with super-spectra, spectra, and subfactors at the upper levels and narrower components below them. Its top level includes an overarching general psychopathology dimension, which reflects broad vulnerability to many forms of disorder. Under the internalizing spectrum, for example, narrower clusters such as fear and distress lie beneath, and specific phenotypes such as social anxiety and insomnia sit lower still. Researchers have also developed a 45-item self-report measure, the Brief HiTOP (B-HiTOP), for broad screening. Its clinical utility is still being tested; a recent review concluded that future work should focus on dissemination and the establishment of clinical utility.

The National Institute of Mental Health (NIMH) Research Domain Criteria (RDoC) takes a different route. Launched in 2009, it is a research framework rather than a diagnostic manual, and it is designed for studying the full range of human behavior from normal to abnormal based on biology, behavior, and context. Its core is a matrix in which domains that group functional constructs (e.g., reward learning, cognitive control) across the rows and units of analysis (e.g., circuit measures, behavioral task data) down the columns. Its stated ultimate aim is precision medicine for psychiatry, though RDoC has not replaced the DSM or ICD in clinical practice.

Biomarkers, neuroimaging and precision psychiatry

No laboratory test, brain scan or genetic profile is used in routine practice to diagnose a mental disorder, and the field's record on biomarkers is mixed. Many early findings from imaging and candidate-gene studies, including the association between a serotonin transporter variant and depression, failed to replicate in larger samples. Neuroimaging has nonetheless produced reproducible patterns. A systematic review of 164 human neuroimaging studies with sample sizes of 194 or greater identified replicated associations with dimensions at five different levels of the hierarchy, which suggests that dimensional phenotypes may yield more stable targets than diagnostic labels. The effect sizes remain modest, however, and it is unclear whether such markers can guide an individual's treatment. Precision psychiatry, which aims to predict which patient will respond to which intervention, depends on large, well-characterized samples and on trials designed to test those predictions prospectively.

Digital phenotyping and sensor-based monitoring

Digital phenotyping uses data from smartphones and wearables to track behavior and physiology in daily life. Passive sensing, which requires no active input from the participant, can capture behavioral, physiological, or activity data (e.g., movement, sleep quality, social interactions) gathered automatically without active interaction. Features that have been studied include mobility, location, phone use, call log, heart rate, sleep, head movements, facial and vocal characteristics, among others. A 2026 systematic review of passive sensing for relapse prediction covered fifty-two studies encompassing 4,814 participants, with most participants having schizophrenia-spectrum disorders, bipolar disorder or major depressive disorder. Some models performed well, with some AUC values reaching 0.8, but the field remains fragmented. Studies vary in devices, outcome measures and statistical methods, and the authors of one review argued that the field would benefit from moving toward agreed standards regarding data descriptions and outcome measures. Continuous monitoring also raises questions about consent, data ownership and data privacy.

Artificial intelligence in prediction and treatment selection

Machine learning models are being developed to forecast suicide attempts, relapse and treatment response from electronic health records, imaging, speech, text and sensor data. Their promise lies in combining many weak signals that clinicians cannot integrate by hand. Their limits are substantial. Models often perform well on the data used to build them and poorly in new settings, so independent external validation is essential. Training data that underrepresent certain ethnic, economic or age groups can produce unequal error rates. Risk algorithms for suicide, for instance, typically flag many people who do not go on to self-harm, which raises the question of what clinical action a flag should trigger. Interpretability, accountability for errors, and the ethics of using predictions that patients may not understand all remain unresolved, and these issues bear on informed consent as well.

Longitudinal cohorts, gene-environment research and prevention

The most important long-term step may be large longitudinal cohorts that follow children and adults over many years, measuring genes, brain development, environment and symptoms together. The US Adolescent Brain Cognitive Development (ABCD) study, which enrolled more than 11,000 children in late childhood, is an example. Such designs can test how polygenic risk interacts with adversity and how epigenetic changes might record early exposures. Still, the central question is practical: whether disorders can be prevented before they begin. Many risk factors are shared across conditions and are only weakly predictive for any individual, so prevention efforts will need to target modifiable processes, and their success will have to be shown in rigorous evaluations rather than assumed from risk models.

References

1. What is a mental disorder? An exemplar-focused approach - PMCpmc.ncbi.nlm.nih.gov
2. DSM-5ebsco.com
3. Towards automated symptoms assessment in mental healtharxiv.org
4. (PDF) The concept of mental disorder: Diagnostic implications of the harmful dysfunction analysisresearchgate.net
5. On Wakefield's harmful dysfunction analysis of mental disorderresearchgate.net
6. Harmful dysfunction and the search for value neutrality in the definition of mental disorder: response to Wakefield, part 2 - ScienceDirectsciencedirect.com
7. A Critique of Wakefield's "Harmful Dysfunction" Analysisscottlilienfeld.com
8. [DEMENTIA IN THE MENTAL DISORDERS CHAPTER OF THE WORLD HEALTH ORGANIZATION INTERNATIONAL CLASSIFICATION OF DISEASES: WHAT HAS BEEN CHANGED FROM ICD-10 TO ICD-11?] - PubMedpubmed.ncbi.nlm.nih.gov
9. Dementia: changes from ICD-10 to ICD-11link.springer.com
10. ICD-11 and mental disorders: important changes, controversies, and future directionslink.springer.com
11. Neurocognitive disorders in ICD‐11: a new proposal and its outcome - Gaebel - 2019 - World Psychiatry - Wiley Online Libraryonlinelibrary.wiley.com
12. Dementia: changes from ICD-10 to ICD-11ncbi.nlm.nih.gov
13. World Health Organization (WHO) ICD-11ipa-online.org
14. What is the DSM-5 Definition of a Mental Disorder?saybrook.edu
15. From Black Bile to the Brain: Tracing Melancholia and Depressionphdnet.mpg.de
16. Melancholiaen.wikipedia.org
17. Mental Health in Ancient Times: The Humors and Their Impactfherehab.com
18. Introductionlink.springer.com
19. Historical Perspectives on the Care and Treatment of the ...scholarworks.wmich.edu
20. The Asylum Movementencyclopedia.com
21. Moral treatmenten.wikipedia.org
22. Moral Treatment - Social Welfare History Projectsocialwelfare.library.vcu.edu
23. Psychiatric institutions in Europe, nineteenth and twentieth centuryehne.fr
24. 19th Century Mental Health Reforms: From Asylums to Moral Therapy - Socio.Healthsocio.health
25. Kraepelin's Final Views on Dementia Praecox - PMC - NIHpmc.ncbi.nlm.nih.gov
26. Dementia praecox to schizophrenia: The first 100 years - Adityanjee - 1999 - Psychiatry and Clinical Neurosciences - Wiley Online Libraryonlinelibrary.wiley.com
27. Psychiatry's contribution to the public stereotype of schizophrenia: Historical considerationsonlinelibrary.wiley.com
28. Kraepelinian dichotomyen.wikipedia.org
29. Eugen Bleuler and schizophrenia - Hektoen Internationalhekint.org
30. A short history of schizophrenia: from Kraepelin to today — Fridafridaneuro.com
31. Applied History of Psychology/DSM and Other Diagnostic Systems - Wikibooks, open books for an open worlden.wikibooks.org
32. DSM-III-R - an overviewsciencedirect.com
33. History of the DSMcourses.lumenlearning.com
34. History of the DSM - PsychDBpsychdb.com
35. Diagnosing the context is as important as diagnosing the individualncbi.nlm.nih.gov
36. DSM ‐ I and DSM ‐ II - Horwitz - Major Reference Works - Wiley Online Libraryonlinelibrary.wiley.com
37. Johns Hopkins UniversityEst. 1876press.jhu.edu
38. 06 - Mental, behavioural or neurodevelopmental disorders - ICD-11 MMSfindacode.com
39. The development of the ICD-11 chapter on mental disordersncbi.nlm.nih.gov
40. The ICD‐11 is now officially in effect - Pezzella - 2022 - World Psychiatry - Wiley Online Libraryonlinelibrary.wiley.com
41. Major Diagnostic Differences Between DSM-5 and ICD-11psychiatrictimes.com
42. Practical implications of ICD-11 personality disorder classificationsbmcpsychiatry.biomedcentral.com
43. Preliminary Scales for ICD-11 Personality Disorder: Self and Interpersonal Dysfunction Plus Five Personality Disorder Trait Domainsncbi.nlm.nih.gov
44. Frontiersfrontiersin.org
45. (PDF) A Comprehensive Comparison of the ICD-11 and DSM–5 Section III Personality Disorder Modelsresearchgate.net
46. Data and Statistics on Autism Spectrum Disordercdc.gov
47. Restored CDCrestoredcdc.org
48. Attention-deficit Hyperactivity Disorder and Autism Spectrum Disorder: Towards Better Diagnosis and Management - PMCpmc.ncbi.nlm.nih.gov
49. Schizophrenia: Background, Diagnostic Criteria (DSM-5-TR), Epidemiologyemedicine.medscape.com
50. Schizophrenia - Psychiatry - MSD Manual Professional Editionmsdmanuals.com
51. Depressive disorder (depression)who.int
52. Anxiety disorderswho.int
53. Mental disorderswho.int
54. Mental disorderswho.int
55. Data on ADHD in Childrencdc.gov
56. World Mental Health Rankings: Global Burden, Disability, and Spendingmhstats.org
57. Global Anxiety Statistics: The Most Common Mental Disorder Worldwidemhstats.org
58. World mental health today Latest datairis.who.int
59. Global, regional and national burden of anxiety and depression disorders from 1990 to 2021, and forecasts up to 2040 - ScienceDirectsciencedirect.com
60. Estimation of the Global Disease Burden of Depression and Anxiety between 1990 and 2044: An Analysis of the Global Burden of Disease Study 2019mdpi.com
61. Global burden of mental disorders among adolescents and young adults, 1990–2021: a systematic analysis of the Global Burden of Diseases Study 2021 - Tian - 2025 - General Psychiatry - Wiley Online Libraryonlinelibrary.wiley.com
62. Burden of Depressive and Anxiety Disorders in Nepal, 1990-2017: An Analysis of Global Burden of Disease Datamedrxiv.org
63. Mental healthhealthdata.org
64. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet Psychiatrythelancet.com
65. WHO sounds alarm as mental health conditions soar past one billion worldwidenews.un.org
66. Mental Health Statistics: Latest Global Data & Trends (2025)statisticsfundamentals.com
67. Depression and Anxiety Among US Children and Young Adultsncbi.nlm.nih.gov
68. Over a billion people living with mental health conditionswho.int
69. Global burden of mental disorders in 204 countries and territories, 1990–2021: results from the global burden of disease study 2021link.springer.com
70. Estimation of the Global Disease Burden of Depression and Anxiety between 1990 and 2044: An Analysis of the Global Burden of Disease Study 2019 - PMCpmc.ncbi.nlm.nih.gov
71. The heritability of alcohol use disorders: a meta-analysis of twin and adoption studiescambridge.org
72. (PDF) The heritability of alcohol use disorders: A meta-analysis of twin and adoption studiesresearchgate.net
73. What clinicians should know about the contribution of modern behavioral genetics to psychiatric problemsncbi.nlm.nih.gov
74. The shared genetic basis of mood instability and psychiatric disorders: A cross‐trait genome‐wide association analysisncbi.nlm.nih.gov
75. Multiple Common Genetic Loci Underlie Eight Psychiatric Disorders - Mass General Advances in Motionadvances.massgeneral.org
76. Multi-trait analysis for genome-wide association study of five psychiatric disordersnature.com
77. [New directions in psychiatric genetics: Genome-wide association studies, polygenic risk score and cross-disorder analysis] - PubMedpubmed.ncbi.nlm.nih.gov
78. Understanding depression and anxiety: 4.2 Evidence for the monoamine hypothesisopen.edu
79. The Monoamine Hypothesis of Depressionresearchgate.net
80. Monoaminergic mechanisms in affective disorders - PubMedpubmed.ncbi.nlm.nih.gov
81. Monoamine Hypotheses of Mood Disorders - Basic Neurochemistry - NCBI Bookshelfncbi.nlm.nih.gov
82. From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder - PMCpmc.ncbi.nlm.nih.gov
83. Looking Beyond the Monoamine Hypothesis - touchNEUROLOGYtouchneurology.com
84. Diathesis–Stress Model In Psychologysimplypsychology.org
85. Diathesis-Stress Model - an overviewsciencedirect.com
86. The neural diathesis-stress model of schizophrenia revisited: An update on recent findings considering illness stage and neurobiological and methodological complexities - ScienceDirectsciencedirect.com
87. Diathesis–stress modelebsco.com
88. A revised and extended systematic review and meta-analysis of the relationship between childhood adversity and adult psychiatric disorder - ScienceDirectsciencedirect.com
89. Cumulative exposure to childhood adversity and risk of adult psychosis: a dose–response meta-analysis - PMCpmc.ncbi.nlm.nih.gov
90. Cumulative adverse childhood experiences and risk of mental disorders: A systematic review and meta-analysis - ScienceDirectsciencedirect.com
91. Adverse childhood experiences and adult psychopathology: A latent class analysis approach - ScienceDirectsciencedirect.com
92. The Social Determinants of Mental Healthpsychiatryonline.org
93. Exploring Associations between Social Determinants of Health and Mental Health Outcomes in Families from Socioeconomically and Racially and Ethnically Diverse Households - PMCpmc.ncbi.nlm.nih.gov
94. The Social Determinants of Mental Health: Psychiatrists’ Roles in Addressing Discrimination and Food Insecuritypsychiatryonline.org
95. Addressing social determinants of health in individuals with mental disorders in clinical practice: review and recommendationsnature.com
96. A revised and extended systematic review and meta-analysis of the relationship between childhood adversity and adult psychiatric disorderresearchgate.net
97. APA - The Structured Clinical Interview for DSM-5®appi.org
98. Structured Clinical Interview for DSM Disorders - an overviewsciencedirect.com
99. (PDF) Reliability of the Structured Clinical Interview for DSM-III-R: An evaluative reviewresearchgate.net
100. Structured Clinical Interview for DSM-IV - an overviewsciencedirect.com
101. Frontiersfrontiersin.org
102. Time Trends in Adolescent Diagnoses of Major Depressive Disorder and Co-occurring Psychiatric Conditions in Electronic Health Recordsncbi.nlm.nih.gov
103. Co-occurring Mental Disorders in Substance Abuse Treatment: the Current Health Care Situation in Germanyncbi.nlm.nih.gov
104. Comorbid mental disorders among adults in the mental health surveillance survey - ScienceDirectsciencedirect.com
105. Kappa Statistics - an overviewsciencedirect.com
106. DSM-III field trials: I. Initial interrater diagnostic reliability - PubMedpubmed.ncbi.nlm.nih.gov
107. DSM-5 Field Trials Generate Mixed Resultsmedscape.com
108. Inter-rater reliability of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I) and Axis II Disorders (SCID II) - PubMedpubmed.ncbi.nlm.nih.gov
109. (PDF) DSM-5 Field Trials in the United States and Canada, Part II: Test-Retest Reliability of Selected Categorical Diagnosesresearchgate.net
110. Efficacy of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Meta-Analysis of Recent Literaturelink.springer.com
111. Cognitive behavioral therapies are evidence-basedsciencedirect.com
112. Internet and Computer-Based Cognitive Behavioral Therapy for Anxiety and Depression in Youth: A Meta-Analysis of Randomized Controlled Outcome Trialsncbi.nlm.nih.gov
113. A Randomized Trial of Dialectical Behavior Therapy Versus General Psychiatric Management for Borderline Personality Disorderpsychiatryonline.org
114. Dialectical behavior therapyen.wikipedia.org
115. Efficacy of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder: A Systematic Review of Randomized Controlled Trials - PubMedpubmed.ncbi.nlm.nih.gov
116. The Effectiveness of 6 versus 12 Months of Dialectical Behavior Therapy for Borderline Personality Disorder: A Noninferiority Randomized Clinical Trialkarger.com
117. Dodo Bird Verdict in Psychotherapyresearchgate.net
118. Is the Dodo bird endangered in the 21st century? A meta-analysis of treatment comparison studies - PubMedpubmed.ncbi.nlm.nih.gov
119. Dodo bird verdicten.wikipedia.org
120. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Reviewncbi.nlm.nih.gov
121. Side Effect Profiles of SSRI Use - Psychiatrist.compsychiatrist.com
122. Management of Antidepressant-Induced Sexual Dysfunction: A Literature Reviewncbi.nlm.nih.gov
123. Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy - UpToDateuptodate.com
124. Electroconvulsive Therapy - an overviewsciencedirect.com
125. Electroconvulsive therapy for treatment-resistant depression - ScienceDirectsciencedirect.com
126. A Model of Placebo Response in Antidepressant Clinical Trialspsychiatryonline.org
127. Neural Predictors of the Antidepressant Placebo Responsencbi.nlm.nih.gov
128. Mental health atlas 2024who.int
129. Mental Health Atlas 2024 - WHO IRIS Repositoryiris.who.int
130. Mental Health Atlas 2024ruralindiaonline.org
131. Mental health care is scarce everywhere — but in poor countries, it barely existsourworldindata.org
132. Mental health service coverage and gaps among adults in Europe: a systematic review - ScienceDirectsciencedirect.com
133. WHO Mental Health Gap Action Programme Intervention Guide (mhGAP-IG): the first pre-service training studyncbi.nlm.nih.gov
134. The Implementation of the WHO Mental Health Gap Intervention Guide (mhGAP-IG) in Ukraine, Armenia, Georgia and Kyrgyz Republicncbi.nlm.nih.gov
135. Psychiatric Institutionalization and Deinstitutionalizationcongress.gov
136. Cycles of reform in the history of psychosis treatment in the United States - PMCpmc.ncbi.nlm.nih.gov
137. Transition of Mental Health Services from Institutional to Community-Based Care Abroad and Its Context for Slovenia—Advantages and Risksncbi.nlm.nih.gov
138. Deinstitutionalisation - an overviewsciencedirect.com
139. Frontiersfrontiersin.org
140. Read "Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research" at NAP.edunationalacademies.org
141. Why we need to pursue both universal and targeted prevention to reduce the incidence of affective and psychotic disorders: Systematic review and meta-analysis - ScienceDirectsciencedirect.com
142. Universal, selective and indicated parenting interventions to prevent the development of adverse mental health outcomes in youth: a meta-review of systematic reviews - PMCpmc.ncbi.nlm.nih.gov
143. Developing the universal unified prevention program for diverse disorders for school-aged childrencapmh.biomedcentral.com
144. Mental Illness Prevention and Mental Health Promotion: When, Who, and Howpsychiatryonline.org
145. The place of school-based strategies for universal, selective and indicated prevention for depressioncambridge.org
146. Duration of Untreated Psychosis and Outcomes in First-Episode Psychosis: Systematic Review and Meta-analysis of Early Detection and Intervention Strategiesacademic.oup.com
147. Early Intervention in Psychosis and Management of First Episode Psychosis in Low- and Lower-Middle-Income Countries: A Systematic Reviewacademic.oup.com
148. Early Detection of First-Episode Psychosis: The Effect on 1-Year Outcome - PMCpmc.ncbi.nlm.nih.gov
149. Coverage of Early Intervention Services for First Episode ...medicaid.gov
150. Duration of untreated psychosis and functional trajectories: A 36-month analysis from EPIC-NOLA clinic, a community early intervention clinic - ScienceDirectsciencedirect.com
151. Limit access to means of suicidewho.int
152. Revisiting evidence of primary prevention of suicide among adult populations: A systematic overview - ScienceDirectsciencedirect.com
153. Preventing Suicide Through Lethal Means Restriction in Pediatric Care - ScienceDirectsciencedirect.com
154. Reducing a Suicidal Person’s Access to Lethal Means of Suicide: A Research Agenda - ScienceDirectsciencedirect.com
155. reduction of mental health related stigma and discriminationdocuments1.worldbank.org
156. How the media can combat mental health stigma and discriminationwho.int
157. Mental Health Stigma and Communication and Their Intersections with Education - PMCpmc.ncbi.nlm.nih.gov
158. A nationally representative survey of the impact of discrimination towards people with mental health problems: SANE’s 2025 National Stigma Report Cardncbi.nlm.nih.gov
159. Human rights framework: An ethical imperative for psychiatry - Neeraj S Gill, 2019doi.org
160. Reframing involuntary treatment as a sentinel event: a model for improving rights-based mental health carencbi.nlm.nih.gov
161. The CRPD Article 12, the limits of reductionist approaches to complex issues and the necessary search for compromise - PMCpmc.ncbi.nlm.nih.gov
162. Mental health law and the UN Convention on the rights of persons with disabilitiesncbi.nlm.nih.gov
163. Interventions to reduce stigma towards people with severe mental illness: Systematic review and meta-analysisresearchgate.net
164. Intergroup contact and mental health stigma: A comparative effectiveness meta-analysis - ScienceDirectsciencedirect.com
165. Effect of Contact-Based Interventions on Stigma and Discrimination: A Critical Examination of the Evidencepsychiatryonline.org
166. The effectiveness of anti-stigma interventions for reducing mental health stigma in young people: A systematic review and meta-analysiscambridge.org
167. Effectiveness of a Brief Digitized Contact-Based Intervention in Improving Mental Health Stigma and Help-Seeking in Young Adults: Mixed Methods Study - ScienceDirectsciencedirect.com
168. Interventions to Reduce Discrimination and Stigma: The State of the Artpsychiatryonline.org
169. insanity defenselaw.cornell.edu
170. The Hinckley Trial's Effect on the Insanity Defensefamous-trials.com
171. Insanity Defensepsycholegalassessments.com
172. The M'Naghten Rule - FindLawfindlaw.com
173. Dusky v. United States: The Competency to Stand Trial Standard - CourtDocketcourtdocket.org
174. Dusky v. United Statesoyez.org
175. Competency evaluation (law)en.wikipedia.org
176. Indiana v. Edwardsen.wikipedia.org
177. A Proposal for the Capacity to Stipulate to Civil Commitment and a 50-State Review of Statutesjaapl.org
178. Civil Commitment in the Psychiatric Emergency Room: II. Mental Disorder Indicators and Three Dangerousness Criteria - PMCpmc.ncbi.nlm.nih.gov
179. Involuntary Civil Commitments: Common Questions and a ...wsipp.wa.gov
180. Nexus between Mental Illness and Dangerousness in Civil Commitmentjaapl.org
181. 9.2 Fundamentals of Civil Commitmentopenoregon.pressbooks.pub
182. Involuntary commitmenten.wikipedia.org
183. Juveniles and Competency to Stand Trial - PMC - NIHpmc.ncbi.nlm.nih.gov
184. Involuntary Civil Commitment: Fourteenth Amendment Due Process Protectionscongress.gov
185. Culture-bound syndrome in ICD-11 and DSM 5 - IP Indian J Neurosciijnonline.org
186. Culture-bound syndromeen.wikipedia.org
187. Conundrum of the Critiques Related to Culture Bound Syndromes and the Way Forward - Swapnajeet Sahoo, Bhavika Rai, Aseem Mehra, Sandeep Grover, Eepsita Mishra, Shaheena Parveen, 2021journals.sagepub.com
188. Culture-bound syndromes: the story of dhat syndromecambridge.org
189. Culture-bound syndromesebsco.com
190. Approaching “highly sensitive person” as a cultural concept of distress: a case-study using the cultural formulation interview in patients with bipolar disorderncbi.nlm.nih.gov
191. Lesson Plan Teacher: Wayne Ha Title: The DSM & Cultural Concepts of Distressapa.org
192. Cultural concepts of distress and assessmentslideshare.net
193. DSM-5 and Culture: A Significant Advancecbdmh.org
194. Cultural Formulation - MMHRCmulticulturalmentalhealth.ca
195. APA - DSM-5 Handbook on the Cultural Formulation Interviewappi.org
196. Cultural Formulation (DSM-5 Section III) and Glossary of Cultural Concepts of Distress (DSM-5 Appendix) Flashcardsquizlet.com
197. Patients’ and clinicians’ experiences of the DSM-5 Cultural Formulation Interview: A mixed method study in a Swedish outpatient settingncbi.nlm.nih.gov
198. Editorial: Clinical implementation of the DSM-5 cultural formulation interviewncbi.nlm.nih.gov
199. Cultural Concepts of Distress - Mental Healthbrightfutures.org
200. Relevance of culture‐bound syndromes in the 21st century - Ventriglio - 2016 - Psychiatry and Clinical Neurosciences - Wiley Online Libraryonlinelibrary.wiley.com
201. Psychpediapsychpedia.com
202. The DSM-5 Cultural Formulation Interview and the Evolution of Cultural Assessment in Psychiatrypsychiatrictimes.com
203. An Introduction to the Cultural Formulation Interviewpsychiatryonline.org
204. Grief, Depression, and the DSM-5 : Journal of Psychiatric Practiceovid.com
205. The Bereavement Exclusion and DSM-5: An Update and Commentary - Innovations in Clinical Neuroscienceinnovationscns.com
206. (PDF) Expansion of the concept of mental disorder in the DSM-5researchgate.net
207. Differences between DSM-IV and DSM-5 as applied to general adult psychiatrycambridge.org
208. (PDF) Financial Ties between DSM-IV Panel Members and the Pharmaceutical Industryresearchgate.net
209. A Comparison of DSM-IV and DSM-5 Panel Members' Financial Associations with Industry: A Pernicious Problem Persistsncbi.nlm.nih.gov
210. Tripartite Conflicts of Interest and High Stakes Patent Extensions in the DSM-5karger.com
211. Grief and Major Depression—Controversy Over Changes in DSM-5 Diagnostic Criteriaaafp.org
212. Complicated Grief Can Be Complicatedpsychologytoday.com
213. Diagnostic inflation in the DSM: A meta-analysis of changes in the stringency of psychiatric diagnosis from DSM-III to DSM-5 - ScienceDirectsciencedirect.com
214. State of the Science: The Hierarchical Taxonomy of Psychopathology (HiTOP) - ScienceDirectsciencedirect.com
215. Using empirically-derived dimensional phenotypes to accelerate clinical neuroscience: the Hierarchical Taxonomy of Psychopathology (HiTOP) frameworknature.com
216. Brief Hierarchical Taxonomy of Psychopathology (B-HiTOP)novopsych.com
217. NIMH RDoC Publications - National Institute of Mental Health (NIMH)nimh.nih.gov
218. Advancing Translational Research Using NIMH Research Domain Criteria and Computational Methods - ScienceDirectsciencedirect.com
219. The Hierarchical Taxonomy of Psychopathology (HiTOP) and the search for neurobiological substrates of mental illness: A systematic review and roadmap for future research - PMCpmc.ncbi.nlm.nih.gov
220. Diagnostic digital phenotyping in schizophrenia-spectrum disorders: a systematic reviewncbi.nlm.nih.gov
221. Digital Phenotyping for Monitoring Mental Disorders: Systematic Review - PMCpmc.ncbi.nlm.nih.gov
222. Digital phenotyping for predicting relapse in psychiatric disorders: a systematic review of passive sensing approacheslink.springer.com
223. Digital Phenotyping of Mental Health using multimodal sensing of multiple situations of interest: A Systematic Literature Review - ScienceDirectsciencedirect.com
224. Hierarchical structuring of psychopathological dimensions in youth: current progress and future steps with the Hierarchical Taxonomy of Psychopathology (HiTOP)link.springer.com
225. The NIMH Research Domain Criteria (RDoC) Project: Precision Medicine for Psychiatrypsychiatryonline.org
226. Diagnostic digital phenotyping in schizophrenia-spectrum disorders: a systematic reviewnature.com